Octamer-binding O
proteins O
from O
B B
or I
HeLa I
cells I
stimulate O
transcription O
of O
the O
immunoglobulin O
heavy-chain O
promoter O
in O
vitro O
. O

Extracts O
of O
the O
B-cell B
line I
, O
BJA-B B
, O
contain O
high O
levels O
of O
NF-A2 O
and O
specifically O
transcribe O
Ig O
promoters O
. O

In O
contrast O
, O
extracts O
from O
HeLa B
cells I
transcribed O
the O
Ig O
promoter O
poorly O
. O

Studies O
with O
inhibitors O
of O
protein O
synthesis O
indicated O
that O
the O
time O
of O
synthesis O
of O
the O
activator O
of O
the O
IL-2 O
gene O
in O
Jurkat B
T I
cells I
corresponds O
to O
the O
time O
of O
appearance O
of O
NFAT-1 O
. O

Characterization O
of O
thyroid O
hormone O
receptors O
in O
human B
IM-9 I
lymphocytes I
. O

As O
a O
first O
step O
towards O
understanding O
the O
mechanism O
of O
thyroid O
hormone O
action O
in O
man O
we O
have O
characterized O
T3 O
binding O
sites O
in O
nuclei O
of O
the O
human B
lymphoblastoid I
line I
, O
IM-9 B
cells I
. O

These O
results O
suggest O
that O
the O
T3 O
binding O
sites O
present O
in O
human B
IM-9 I
lymphocyte I
nuclei O
and O
extracts O
thereof O
are O
thyroid O
hormone O
receptors O
. O

Further O
studies O
show O
that O
genes O
governing O
the O
expression O
of O
class O
II O
antigens O
fall O
into O
at O
least O
three O
complementation O
groups O
; O
two O
of O
these O
were O
previously O
unidentified O
in O
mutant B
cell I
lines I
generated O
in O
vitro O
. O

Though O
the O
mutation O
in O
at O
least O
one O
mutant B
line I
generated O
in O
vitro O
( O
RJ2.2.5 B
) O
affects O
products O
functioning O
via O
interaction O
with O
the O
X O
box O
, O
clear O
alterations O
in O
either O
NFX1.1 O
or O
NFX1.2 O
are O
not O
found O
in O
any O
of O
the O
mutant B
cell I
lines I
. O

Properties O
of O
glucocorticoid O
receptors O
in O
Epstein-Barr B
virus-transformed I
lymphocytes I
from O
patients O
with O
familial O
cortisol O
resistance O
. O

In O
a O
previous O
report O
of O
two O
patients O
with O
familial O
glucocorticoid O
resistance O
due O
to O
reduced O
numbers O
of O
glucocorticoid O
receptors O
( O
GR O
) O
, O
we O
have O
shown O
decreased O
numbers O
of O
GR O
in O
peripheral O
mononuclear O
cells O
and O
cultured B
fibroblasts I
but O
normal O
affinity O
of O
GR O
in O
both O
patients O
. O

Reduced O
numbers O
and O
normal O
affinity O
of O
GR O
were O
found O
in O
the O
Epstein-Barr B
virus-transformed I
lymphocytes I
from O
both O
patients O
while O
the O
son O
and O
daughter O
had O
normal O
numbers O
and O
affinity O
of O
GR O
. O

These O
abnormal O
properties O
of O
GR O
( O
reduced O
numbers O
of O
GR O
) O
were O
preserved O
in O
the O
transformed B
cells I
from O
the O
patients O
. O

From O
several O
findings O
, O
including O
the O
absence O
of O
OTF-2B O
( O
but O
not O
OTF-2A O
) O
from O
a O
lymphocyte B
line I
that O
can O
not O
respond O
to O
the O
IgH O
enhancer O
, O
we O
propose O
a O
role O
of O
the O
novel O
octamer O
factor O
in O
the O
long O
range O
activation O
by O
the O
IgH O
enhancer O
. O

Inhibition O
of O
interleukin O
2 O
-induced O
proliferation O
of O
cloned B
murine I
T I
cells I
by O
glucocorticoids O
. O

The O
ability O
of O
glucocorticoids O
to O
inhibit O
interleukin O
2 O
( O
IL O
2 O
) O
-induced O
T O
cell O
proliferation O
in O
two O
cytotoxic B
T I
cell I
( I
CTL I
) I
clones I
has O
been O
studied O
. O

A O
complete O
inhibition O
of O
DNA O
synthesis O
by O
dexamethasone O
( O
Dx O
) O
could O
be O
observed O
when O
IL B
2-depleted I
cultures I
of O
CTL B
were O
either O
incubated O
for O
6 O
h O
with O
the O
hormone O
prior O
to O
the O
addition O
of O
IL O
2 O
or O
treated O
simultaneously O
with O
Dx O
and O
a O
low O
concentration O
of O
IL O
2 O
. O

Furthermore O
, O
supernatant O
from O
Dx-treated O
CTL B
contained O
a O
nondialyzable O
factor O
which O
inhibited O
DNA O
synthesis O
and O
cell O
growth O
of O
CTL B
clones I
induced O
by O
IL O
2 O
. O

The O
enhancer-binding O
factor O
NF-kappa O
B O
, O
which O
is O
found O
only O
in O
cells O
that O
transcribe O
immunoglobulin O
light O
chain O
genes O
, O
has O
been O
purified O
from O
nuclear O
extracts O
of O
Namalwa B
cells I
( O
human B
Burkitt I
lymphoma I
cells I
) O
by O
sequence-specific O
DNA O
affinity O
chromatography O
. O

Decreased O
deoxyribonucleic O
acid O
binding O
of O
glucocorticoid-receptor O
complex O
in O
cultured O
skin B
fibroblasts I
from O
a O
patient O
with O
the O
glucocorticoid O
resistance O
syndrome O
. O

To O
explain O
the O
end-organ O
resistance O
to O
cortisol O
, O
the O
glucocorticoid O
receptors O
( O
GR O
) O
in O
peripheral O
mononuclear O
leukocytes O
and O
cultured B
skin I
fibroblasts I
from O
a O
forearm O
skin O
biopsy O
were O
characterized O
and O
compared O
with O
the O
results O
of O
similar O
studies O
in O
normal O
subjects O
. O

In O
the O
cytosol O
of O
cultured B
skin I
fibroblasts I
from O
the O
patient O
, O
there O
was O
also O
decreased O
binding O
capacity O
. O

The O
thermal O
stability O
and O
the O
sedimentation O
coefficient O
in O
a O
sucrose O
density O
gradient O
of O
the O
receptors O
in O
the O
cytosol O
of O
cultured B
skin I
fibroblasts I
from O
the O
patient O
and O
normal O
subjects O
were O
similar O
. O

GR B
complex I
activation I
, O
analyzed O
by O
DEAE-cellulose B
chromatography I
, O
was O
decreased O
in O
the O
patient O
. O

The O
regulation O
of O
GM-CSF O
expression O
is O
seen O
in O
both O
normal O
human O
mitogen-activated O
T O
lymphocytes O
and O
T B
lymphocytes I
from I
a I
line I
( I
S-LB1 I
) I
transformed I
with I
human I
T I
cell I
lymphotropic I
virus I
1 I
( O
HTLV-1 O
) O
. O

In O
contrast O
, O
cells O
from O
a O
HTLV-1 B
transformed I
T I
lymphocyte I
line I
( O
Ab-VDR B
) O
established O
from O
a O
patient O
with O
vitamin O
D-resistant O
rickets O
type O
II O
with O
undetectable O
1 O
, O
25 O
( O
OH O
) O
2D3 O
cellular O
receptors O
are O
resistant O
to O
the O
action O
of O
1 O
, O
25 O
( O
OH O
) O
2D3 O
. O

The O
effects O
of O
cortisol O
on O
the O
natural O
killer O
( O
NK O
) O
activity O
of O
human O
peripheral O
blood O
mononuclear O
( O
PBM O
) O
cells O
were O
studied O
in O
vitro O
using O
a O
direct O
4-h O
51Cr-release O
assay O
and O
K B
562 I
cell I
line I
as O
a O
target O
. O

Octamer-containing O
fragments O
have O
been O
reported O
to O
bind O
a O
factor O
present O
in O
nuclear O
extracts O
of O
human B
cell I
lines I
; O
however O
, O
identical O
binding O
activity O
was O
detected O
in O
both O
B B
lymphoid I
and I
non-lymphoid I
cells I
. O

The O
promoters O
of O
the O
adenovirus O
2 O
major O
late O
gene O
, O
the O
mouse O
beta-globin O
gene O
, O
the O
mouse O
immunoglobulin O
VH O
gene O
and O
the O
LTR O
of O
the O
human O
T-lymphotropic O
retrovirus O
type O
I O
were O
tested O
for O
their O
transcription O
activities O
in O
cell-free O
extracts O
of O
four O
cell O
lines O
; O
HeLa B
, O
CESS B
( O
Epstein-Barr B
virus-transformed I
human I
B I
cell I
line I
) O
, O
MT-1 B
( O
HTLV-I-infected B
human I
T I
cell I
line I
without O
viral O
protein O
synthesis O
) O
, O
and O
MT-2 B
( O
HTLV-I-infected B
human I
T I
cell I
line I
producing O
viral O
proteins O
) O
. O

LTR O
was O
preferentially O
transcribed O
in O
the O
extracts O
of O
MT-2 B
although O
the O
other O
three O
genes O
were O
transcribed O
with O
relatively O
constant O
efficiencies O
in O
different O
extracts O
. O

Interestingly O
, O
a O
factor O
showing O
similar O
binding O
specificity O
to O
IgNF-A O
is O
also O
present O
in O
human B
HeLa I
cells I
. O

The O
glucocorticoid O
target O
tissues O
that O
have O
been O
examined O
( O
circulating O
mononuclear O
lymphocytes O
and O
cultured B
skin I
fibroblasts I
) O
have O
normal O
concentrations O
of O
glucocorticoid O
receptors O
with O
decreased O
affinity O
for O
dexamethasone O
. O

Separate O
epitopes O
in O
VP22 O
were O
defined O
for O
T-cell B
clones I
from O
each O
of O
three O
patients O
. O

Some O
tegument-specific B
CD4 I
T-cell I
clones I
exhibited O
cytotoxic O
activity O
against O
HSV-infected O
cells O
. O

U937 B
cells I
differentiated O
with O
PMA O
in O
nonadherent B
culture I
were O
shown O
to O
express O
two O
fibrinogen-binding O
integrins O
, O
predominately O
CD11b/CD18 O
, O
and O
to O
a O
lesser O
extent O
, O
CD11c/CD18 O
. O

To O
determine O
the O
effects O
on O
transcriptional O
regulation O
, O
U937 B
cells I
were O
transfected O
with O
a O
plasmid O
containing O
the O
HIV-1 O
enhancer O
( O
bearing O
two O
NF-kappa O
B O
sites O
) O
coupled O
to O
a O
chloramphenicol O
acetyltransferase O
( O
CAT O
) O
reporter O
. O

Peripheral O
blood O
T O
cells O
and O
monocytes O
and O
B B
cell I
lines I
derived O
from O
patients O
with O
lupus O
express O
estrogen O
receptor O
transcripts O
similar O
to O
those O
of O
normal O
cells O
. O

Epstein-Barr O
virus-transformed O
B B
cell I
lines I
( O
n O
= O
7 O
) O
and O
B B
cell I
hybridomas I
( O
n O
= O
2 O
) O
established O
from O
patients O
with O
SLE O
and O
a O
healthy O
individual O
were O
used O
as O
a O
B O
cell O
source O
. O

Using O
the O
1G5 B
cell I
line I
harbouring O
the O
luciferase O
reporter O
gene O
under O
the O
control O
of O
the O
HIV-1 O
LTR O
, O
it O
was O
first O
found O
that O
culture O
protein O
filtrates O
( O
CFP O
) O
from O
M. O
tuberculosis O
or O
purified O
ManLAM O
could O
activate O
HIV-1 O
LTR-dependent O
gene O
expression O
unlike O
similarly O
prepared O
CFP O
extracts O
devoid O
of O
ManLAM O
. O

Transient O
expression O
analyses O
in O
cells O
of O
neuroglial O
and O
lymphocytic O
origin O
demonstrated O
that O
some O
of O
these O
LTRs O
had O
activities O
which O
varied O
significantly O
from O
the O
LAI O
LTR O
in O
U-373 B
MG I
cells I
( O
an O
astrocytoma B
cell I
line I
) O
as O
well O
as O
in O
Jurkat B
cells I
( O
a O
CD4-positive B
lymphocyte I
cell I
line I
) O
. O

While O
LTRs O
which O
demonstrated O
the O
highest O
activities O
in O
U-373 B
MG I
cells I
also O
yielded O
high O
activities O
in O
Jurkat B
cells I
, O
the O
LTRs O
were O
generally O
more O
active O
in O
Jurkat B
cells I
when O
compared O
to O
the O
LAI O
LTR O
. O

Transcriptional O
regulation O
of O
the O
gene O
for O
the O
myeloid O
calcium O
binding O
protein O
, O
MRP14 O
, O
was O
investigated O
in O
human B
monocytic I
leukemia I
cell I
lines I
. O

The O
MRP14 O
gene O
was O
not O
expressed O
in O
monoblastic B
ML-1 I
cells I
, O
promonocytic B
U-937 I
cells I
, O
or O
promyelocytic B
HL-60 I
cells I
. O

On O
the O
other O
hand O
, O
the O
gene O
was O
expressed O
in O
monocytic B
THP-1 I
cells I
and O
in O
the O
HL-60 B
cells I
treated O
with O
1 O
, O
25-dihydroxyvitamin O
D3 O
( O
VD3 O
) O
. O

The O
level O
of O
MRP14 O
in O
VD3-treated O
HL-60 B
cells I
was O
two-fold O
higher O
than O
that O
in O
THP-1 B
cells I
. O

Among O
several O
known O
transcription O
factor O
binding O
motifs O
, O
nuclear O
protein O
( O
s O
) O
of O
VD3-treated B
HL-60 I
cells I
and I
THP-1 I
cells I
bound O
to O
the O
CCAAT/enhancer O
binding O
protein O
( O
C/EBP O
) O
-binding O
motif O
that O
was O
located O
in O
the O
upstream O
region O
of O
the O
MRP14 O
gene O
( O
-81 O
) O
, O
as O
evidenced O
by O
the O
competitive O
gel O
mobility-shift O
assay O
. O

An O
antibody O
for O
C/EBP O
alpha O
super-shifted O
the O
nucleoprotein O
complex O
in O
THP-1 B
cells I
but O
not O
in O
the O
VD3-treated B
HL-60 I
cells I
, O
whereas O
an O
antibody O
for O
C/EBP O
beta O
blocked O
the O
formation O
of O
the O
complex O
with O
the O
nuclear O
factor O
of O
the O
HL-60 B
cells I
but O
not O
with O
that O
of O
THP-1 B
cells I
. O

Thus O
, O
it O
was O
concluded O
that O
C/EBP O
alpha O
and O
-beta O
were O
able O
to O
bind O
to O
the O
C/EBP O
motif O
, O
and O
that O
C/EBP O
alpha O
bound O
to O
the O
motif O
in O
THP-1 B
cells I
and O
C/EBP O
beta O
bound O
to O
that O
in O
the O
VD3-treated B
HL-60 I
cells I
. O

Furthermore O
, O
to O
examine O
the O
transcriptional O
activity O
of O
the O
C/EBP O
motif O
, O
we O
transfected O
several O
constructed O
luciferase O
reporter O
DNAs O
into O
HL-60 B
cells I
and O
THP-1 B
cells I
. O

The O
luciferase O
activity O
of O
the O
C/EBP O
motif O
in O
HL-60 B
cells I
was O
increased O
by O
VD3 O
treatment O
. O

The O
C/EBP O
motif O
in O
the O
MRP14 O
gene O
was O
confirmed O
to O
function O
as O
a O
regulatory O
region O
in O
VD3-treated B
HL-60 I
cells I
and I
THP-1 I
cells I
by O
the O
assay O
. O

Since O
C/EBP O
beta O
was O
also O
detected O
in O
VD3-untreated B
HL-60 I
cells I
by O
immunoblotting O
, O
VD3 O
activated O
C/EBP O
beta O
to O
bind O
to O
the O
motif O
, O
probably O
through O
post-translational O
modification O
. O

Steroid O
metabolism O
was O
investigated O
in O
cultured B
human I
B-lymphoblastoid I
cells I
( O
B-LCL B
) O
, O
and O
peripheral O
blood O
T O
and O
B O
cells O
. O

There O
was O
minimal O
expression O
of O
HSD3B1 O
and O
HSD3B2 O
( O
3beta-hydroxysteroid O
dehydrogenase O
I O
and O
II O
) O
in O
B-LCL B
and O
T O
cells O
. O

In O
this O
report O
the O
biochemical O
properties O
of O
the O
heterotrimeric O
NF-Y O
complex O
have O
been O
characterized O
during O
stage-specific O
B-cell O
development O
, O
and O
in O
several O
class B
II- I
mutant I
B-cell I
lines I
, O
which O
represent O
distinct O
bare O
lymphocyte O
syndrome O
class O
II O
genetic O
complementation O
groups O
. O

The O
NF-Y O
complex O
derived O
from O
class O
II+ O
mature O
B-cells O
bound O
with O
high O
affinity O
to O
anion O
exchangers O
, O
and O
eluted O
as O
an O
intact O
trimeric O
complex O
, O
whereas O
, O
NF-Y O
derived O
from O
class O
II- O
plasma O
B-cells O
, O
and O
from O
bare B
lymphocyte I
syndrome I
group I
II I
cell I
lines I
, O
RJ2.2.5 B
and O
RM3 B
, O
dissociated O
into O
discrete O
NF-YA O
and O
NF-YB O
: O
C O
subunit O
fractions O
. O

We O
found O
that O
the O
conversion O
of O
70Z/3 B
pre-B I
lymphocytes I
to O
cells O
with O
a O
macrophage-like O
phenotype O
is O
associated O
with O
the O
loss O
of O
E2A O
and O
EBF O
. O

Moreover O
, O
we O
show O
that O
ectopic O
expression O
of O
the O
E2A O
protein O
E12 O
in O
this O
macrophage B
line I
results O
in O
the O
induction O
of O
many O
B O
lineage O
genes O
, O
including O
EBF O
, O
IL7Ralpha O
, O
lambda5 O
, O
and O
Rag-1 O
, O
and O
the O
ability O
to O
induce O
kappa O
light O
chain O
in O
response O
to O
mitogen O
. O

Our O
data O
demonstrate O
that O
, O
in O
the O
context O
of O
this O
macrophage B
line I
, O
E12 O
induces O
expression O
of O
EBF O
and O
together O
these O
transcription O
factors O
coordinately O
regulate O
numerous O
B O
lineage-associated O
genes O
. O

Use O
of O
transfected B
liver I
cells I
to O
evaluate O
potential O
mechanisms O
of O
alcohol-induced O
liver O
injury O
[ O
see O
comments O
] O

The O
objectives O
of O
these O
studies O
were O
to O
investigate O
mechanisms O
for O
induction O
of O
an O
injurious O
factor O
( O
IL-8 O
) O
and O
a O
protective O
factor O
( O
MnSOD O
) O
in O
the O
HepG2 B
human I
hepatoma I
cell I
line I
. O

In O
the O
first O
set O
of O
experiments O
, O
IL-8 O
gene O
reporter O
constructs O
were O
used O
to O
transiently O
transfect O
a O
derivative O
( O
MVh2E1-9 B
) O
of O
the O
HepG2 B
cell I
line I
which O
expresses O
P-4502E1 O
and O
metabolizes O
ethanol O
. O

In O
the O
second O
set O
of O
experiments O
, O
HepG2 B
cells I
were O
cultured O
in O
25 O
to O
100 O
mmol O
concentrations O
of O
ethanol O
. O

Both O
TNF O
and O
ethanol O
increased O
HepG2 B
cell I
MnSOD O
activity O
in O
short-term O
( O
72 O
hr O
) O
cultures O
with O
ethanol O
. O

Further O
studies O
are O
needed O
to O
assess O
the O
effect O
of O
this O
diminished O
induction O
of O
MnSOD O
with O
chronic O
ethanol O
culture O
on O
HepG2 B
cell I
susceptibility O
to O
TNF B
cytotoxicity I
. O

We O
conclude O
that O
transfected O
liver B
cell I
lines I
can O
be O
used O
to O
evaluate O
mechanisms O
for O
increased O
injurious O
factors O
and O
decreased O
protective O
factors O
in O
alcoholic O
liver O
injury O
. O

MPs O
and O
HeLa B
cells I
subjected O
to O
hypoxia O
( O
pO2 O
approximately O
13 O
torr O
) O
had O
increased O
levels O
of O
tissue O
factor O
transcripts O
( O
approximately O
18-fold O
) O
and O
an O
increased O
rate O
of O
transcription O
( O
approximately O
15-fold O
) O
, O
based O
on O
nuclear O
run-on O
analysis O
. O

Gel-shift O
analysis O
of O
nuclear O
extracts O
from O
hypoxic O
MPs O
and O
HeLa B
cells I
demonstrated O
increased O
DNA-binding O
activity O
at O
the O
serum O
response O
region O
( O
SRR O
; O
-111/+14 O
bp O
) O
of O
the O
tissue O
factor O
promoter O
at O
Egr-1 O
motifs O
. O

Using O
32P-labeled O
Egr O
consensus O
oligonucleotide O
, O
we O
observed O
induction O
of O
DNA-binding O
activity O
in O
nuclear O
extracts O
from O
hypoxic O
lung O
and O
HeLa B
cells I
because O
of O
activation O
of O
Egr-1 O
, O
by O
means O
of O
supershift O
analysis O
. O

Transient O
transfection O
of O
HeLa B
cells I
with O
chimeric O
plasmids O
containing O
wild-type O
or O
mutant O
SRR O
from O
the O
tissue O
factor O
promoter O
showed O
that O
intact O
Sp1 O
sites O
are O
necessary O
for O
basal O
promoter O
activity O
, O
whereas O
the O
integrity O
of O
Egr-1 O
sites O
was O
required O
for O
hypoxia-enhanced O
expression O
. O

Kinetics O
of O
cytokine O
and O
NFAT O
gene O
expression O
in O
human B
interleukin-2-dependent I
T I
lymphoblasts I
stimulated O
via O
T-cell O
receptor O
. O

The O
transcriptional O
regulatory O
region O
of O
the O
gp34 O
gene O
was O
activated O
by O
HTLV-I O
Tax O
in O
the O
human B
T I
cell I
line I
Jurkat I
, O
in O
which O
endogenous O
gp34 O
is O
induced O
by O
Tax O
. O

Unlike O
typical O
NF-kappaB O
elements O
, O
the O
NF-kappaB-like O
elements O
in O
gp34 O
were O
not O
activated O
by O
treatment O
of O
Jurkat B
cells I
with O
phorbol O
ester O
despite O
induction O
of O
the O
NF-kappaB O
-like O
binding O
activity O
. O

beta-Amyloid O
fibrils O
activate O
parallel O
mitogen-activated O
protein O
kinase O
pathways O
in O
microglia O
and O
THP1 B
monocytes I
. O

We O
report O
that O
exposure O
of O
primary O
rat O
microglia O
and O
human B
THP1 I
monocytes I
to O
fibrillar O
Abeta O
results O
in O
the O
tyrosine O
kinase O
-dependent O
activation O
of O
two O
parallel O
signal O
transduction O
cascades O
involving O
members O
of O
the O
mitogen-activated O
protein O
kinase O
( O
MAPK O
) O
superfamily O
. O

Abeta O
stimulated O
the O
rapid O
, O
transient O
activation O
of O
extracellular O
signal-regulated O
kinase O
1 O
( O
ERK1 O
) O
and O
ERK2 O
in O
microglia O
and O
ERK2 O
in O
THP1 B
monocytes I
. O

Exposure O
of O
microglia O
and O
THP1 B
monocytes I
to O
Abeta O
resulted O
in O
the O
activation O
of O
RSK1 O
and O
RSK2 O
and O
phosphorylation O
of O
cAMP O
response O
element-binding O
protein O
at O
Ser133 O
, O
providing O
a O
mechanism O
for O
Abeta O
-induced O
changes O
in O
gene O
expression O

In O
this O
study O
, O
we O
analyzed O
normal O
and O
malignant O
lymphoid O
tissues O
and O
cell B
lines I
, O
including O
102 O
cases O
of O
B-cell O
NHL O
, O
23 O
cases O
of O
T- O
and O
null-cell O
NHL O
, O
and O
18 O
cases O
of O
Hodgkin O
's O
disease O
. O

Western O
blot O
analysis O
showed O
a O
52-kD O
BSAP O
band O
in O
B-cell B
lines I
, O
but O
not O
in O
non-B-cell B
or I
plasma I
cell I
lines I
. O

Isolation O
and O
analysis O
of O
a O
T B
cell I
clone I
variant I
exhibiting O
constitutively O
phosphorylated O
Ser133 O
cAMP O
response O
element-binding O
protein O
. O

PCNA O
transcription O
is O
regulated O
in O
part O
through O
tandem O
CRE O
sequences O
in O
the O
promoter O
and O
CRE O
binding O
proteins O
; O
IL-2 O
stimulates O
CREB O
phosphorylation O
in O
the O
resting B
cloned I
T I
lymphocyte I
, O
L2 B
. O

After O
culturing O
L2 B
cells I
for O
greater O
than O
91 O
days O
, O
we O
consistently O
isolate O
a O
stable O
variant O
that O
exhibits O
constitutive O
CREB O
phosphorylation O
. O

L2 B
and I
L2 I
variant I
cells I
were O
tested O
for O
IL-2 O
responsiveness O
and O
rapamycin O
sensitivity O
with O
respect O
to O
specific O
kinase O
activity O
, O
PCNA O
expression O
and O
proliferation O
. O

In O
L2 B
cells I
, O
IL-2 O
stimulated O
and O
rapamycin O
inhibited O
the O
following O
: O
cAMP-independent O
CREB O
kinase O
activity O
, O
PCNA O
expression O
and O
proliferation O
. O

In O
L2 B
variant I
cells I
, O
CREB O
kinase O
activity O
was O
constitutively O
high O
; O
IL-2 O
stimulated O
and O
rapamycin O
blocked O
PCNA O
expression O
and O
proliferation O
. O

These O
results O
indicate O
that O
IL-2 O
induces O
a O
rapamycin-sensitive O
, O
cAMP-independent O
CREB O
kinase O
activity O
in O
L2 B
cells I
. O

CS O
at O
50-200 O
microM O
reduced O
tumor O
necrosis O
factor O
( O
TNF O
) O
, O
interleukin-1 O
( O
IL-1 O
) O
, O
and O
IL-6 O
activities O
in O
the O
culture O
supernatants O
from O
LPS-stimulated B
human I
blood I
monocytes I
without O
cytotoxicity O
. O

The O
level O
of O
nm23-H1 O
mRNA O
in O
CML B
cells I
at O
the O
chronic O
phase O
was O
as O
high O
as O
that O
in O
bone O
marrow O
cells O
from O
healthy O
volunteers O
. O

We O
first O
developed O
two O
thymidine B
kinase I
( I
tk I
) I
inducible I
human I
cell I
lines I
using O
the O
Gal4-Estrogen O
receptor O
system O
. O

In O
our O
TK6i-G3 B
and I
G9 I
tk I
heterozygous I
cell I
lines I
, O
the O
active O
tk O
allele O
is O
linked O
to O
an O
inducible O
promoter O
element O
. O

Spontaneous O
mutation O
rate O
was O
significantly O
decreased O
in O
human B
cell I
lines I
after O
induction O
in O
contrast O
to O
the O
report O
in O
yeast O
. O

A O
third O
member O
of O
the O
family O
( O
MNP-3 O
) O
is O
expressed O
in O
PMA B
induced I
HL60 I
cells I
and O
probably O
has O
a O
role O
in O
monocyte O
differentiation O
. O

In O
TF-1 B
cells I
, O
an O
erythroleukemia B
cell I
line I
, O
granulocyte-macrophage O
colony-stimulating O
factor O
( O
GM-CSF O
) O
and O
erythropoietin O
( O
Epo O
) O
greatly O
enhanced O
Bcl-3 O
expression O
at O
both O
the O
protein O
and O
mRNA O
levels O
in O
association O
with O
stimulation O
of O
proliferation O
. O

Upon O
stimulation O
of O
TF-1 B
cells I
with O
GM-CSF O
or O
Epo O
, O
the O
nuclear O
translocation O
of O
Bcl-3 O
was O
dramatically O
enhanced O
. O

Overexpression O
of O
Bcl-3 O
in O
TF-1 B
cells I
by O
transient O
transfection O
along O
with O
the O
NF-kappaB O
factors O
p50 O
or O
p52 O
resulted O
in O
significant O
induction O
of O
an O
human O
immunodeficiency O
virus-type O
1 O
( O
HIV-1 O
) O
kappaB-TATA-luceriferase O
reporter O
plasmid O
, O
demonstrating O
that O
Bcl-3 O
has O
a O
positive O
role O
in O
transactivation O
of O
kappaB-containing O
genes O
in O
erythroid O
cells O
. O

Bcl-3 O
in O
nuclear O
extracts O
of O
TF-1 B
cells I
bound O
to O
a O
kappaB O
enhancer O
in O
the O
c-myb O
promoter O
together O
with O
NF-kappaB2/p52 O
and O
this O
binding O
activity O
was O
enhanced O
by O
GM-CSF O
stimulation O
. O

Furthermore O
, O
cotransfection O
of O
Bcl-3 O
with O
p52 O
or O
p50 O
in O
TF-1 B
cells I
resulted O
in O
significant O
activation O
of O
a O
c-myb O
kappaB-TATA-luceriferase O
reporter O
plasmid O
. O

A O
synthetic O
peptide O
consisting O
of O
the O
Kaposi O
fibroblast O
growth O
factor O
signal O
sequence O
fused O
to O
the O
5-lipoxygenase639-656 O
bipartite O
nuclear O
localizing O
sequence O
has O
a O
prominent O
inhibitory O
effect O
on O
5-lipoxygenase O
catalysis O
in O
granulocytic O
HL-60 B
cells I
activated O
by O
calcium O
ionophor O
A23187 O
. O

The O
peptide O
also O
inhibited O
redistribution O
of O
5-lipoxygenase O
from O
the O
cytosol O
to O
the O
nuclear O
membrane O
of O
HL-60 B
cells I
stimulated O
by O
A23187 O
. O

5-Lipoxygenase O
protein O
was O
detected O
in O
nuclear O
factor O
kappaB O
( O
NF-kappaB O
) O
p65 O
subunit O
immunoprecipitate O
fractions O
prepared O
from O
HL-60 B
cell I
lysates O
. O

We O
have O
demonstrated O
that O
in O
both O
HTLV-1-infected O
cells O
and O
Tax-expressing B
JPX-9 I
cells I
, O
TR3/nur77 O
is O
highly O
expressed O
, O
whereas O
neither O
NOR-1 O
nor O
NOT O
expression O
is O
detectable O
. O

In O
Jurkat B
T I
cells I
, O
inhibition O
of O
PP2A O
activity O
by O
small O
t O
antigen O
enhanced O
activation O
of O
CREB O
-mediated O
transcription O
by O
CaMKIV O
. O

We O
have O
investigated O
the O
effect O
of O
hypoxia O
both O
on O
MCP-1 O
expression O
in O
ovarian B
cancer I
cell I
lines I
and O
monocyte O
migration O
. O

By O
using O
purified B
human I
erythroid I
colony-forming I
cells I
( O
ECFC B
) O
, O
we O
have O
found O
that O
SCF O
and O
EPO O
synergistically O
activate O
MAP O
kinase O
( O
MAPK O
, O
ERK1/2 O
) O
, O
which O
correlates O
with O
the O
cell O
growth O
and O
thus O
may O
be O
responsible O
for O
the O
synergistic O
effects O
. O

Antioxidant O
regulation O
of O
phorbol O
ester-induced O
adhesion O
of O
human B
Jurkat I
T-cells I
to O
endothelial O
cells O
. O

The O
effects O
of O
clinically O
safe O
antioxidants O
in O
the O
regulation O
of O
adhesion O
molecule O
expression O
in O
human O
endothelial O
cells O
( O
ECV O
) O
, O
and O
adherence O
of O
human B
Jurkat I
T I
cells I
to O
ECV O
cells O
were O
investigated O
. O

Inhibition O
of O
PMA-induced O
ICAM-1 O
and O
VCAM-1 O
expression O
as O
well O
as O
PMA-induced O
adhesion O
of O
Jurkat B
T-cells I
to O
ECV O
cells O
by O
alpha-lipoate O
was O
dose O
dependent O
( O
50-250 O
microM O
) O
. O

Using O
the O
Raji B
B I
cell I
lymphoma I
, O
which O
express O
similar O
levels O
of O
CD80 O
and O
CD86 O
, O
it O
was O
found O
that O
T O
cell O
proliferation O
was O
mainly O
co-stimulated O
by O
CD80 O
. O

To O
further O
characterize O
the O
consequences O
of O
this O
biased O
co-stimulatory O
dependency O
, O
we O
employed O
a O
well-defined O
system O
of O
transfected O
CHO B
cells I
expressing O
human O
MHC O
class O
II O
together O
with O
CD80 O
, O
CD86 O
or O
CD80 O
and O
CD86 O
. O

To O
analyze O
IL-2 O
transcriptional O
activity O
in O
CD80 O
and O
CD86 O
co-stimulated O
T O
cells O
we O
used O
Jurkat B
T I
cells I
transfected O
with O
luciferase O
reporter O
gene O
constructs O
. O

We O
report O
here O
that O
the O
DR3 O
gene O
locus O
is O
tandemly O
duplicated O
on O
human O
chromosome O
band O
1p36.2-p36.3 O
and O
that O
these O
genes O
are O
hemizygously O
deleted O
and/or O
translocated O
to O
another O
chromosome O
in O
neuroblastoma B
( I
NB I
) I
cell I
lines I
with O
amplified O
MYCN O
. O

In O
most O
NB B
cell I
lines I
, O
both O
the O
DR3 O
and O
the O
DR3L O
sequences O
are O
simultaneously O
deleted O
and/or O
translocated O
to O
another O
chromosome O
. O

Finally O
, O
DR3/ O
Wsl-1 O
protein O
expression O
is O
quite O
variable O
among O
these O
NB B
cell I
lines I
, O
with O
very O
low O
or O
undetectable O
levels O
in O
7 O
of O
17 O
NB B
cell I
lines I

The O
effect O
of O
cycloheximide O
on O
granulocyte/macrophage O
progenitors O
( O
CFU-GM O
) O
after O
in O
vitro O
Ara-C O
exposure O
was O
examined O
using O
normal O
human O
bone O
marrow O
, O
malignant O
progenitors O
from O
patients O
with O
chronic O
myelogenous O
leukemia O
( O
CML O
) O
, O
and O
clonogenic B
cells I
from O
the O
human B
acute I
nonlymphocytic I
leukemia I
cell I
lines I
HL-60 I
and I
KG-1 I
. O

Mononuclear B
or I
clonogenic I
cells I
were O
incubated O
for O
one O
hour O
with O
cycloheximide O
, O
followed O
by O
the O
addition O
, O
for O
three O
or O
17 O
hours O
, O
of O
Ara-C O
before O
being O
plated O
in O
a O
methylcellulose O
culture O
system O
. O

Similar O
cycloheximide O
pretreatment O
of O
CML O
progenitors O
and O
clonogenic B
HL-60 I
and I
KG-1 I
cells I
failed O
to O
protect O
CFU-GM O
from O
Ara-C-induced O
cytotoxicity O
. O

We O
have O
examined O
mononuclear B
cell I
preparations I
from O
patients O
with O
chronic O
myeloid O
leukemia O
[ O
CML O
] O
for O
binding O
of O
and O
response O
to O
1 O
, O
25-dihydroxycholecalciferol O
[ O
1 O
, O
25- O
( O
OH O
) O
2D3 O
] O
. O

Subcellular O
fractionation O
of O
labeled B
cells I
showed O
that O
binding O
was O
restricted O
to O
cytosols O
and O
nuclei O
. O

In O
addition O
, O
cytosols O
prepared O
from O
a O
mixture O
of O
CML B
cells I
and O
1 B
, I
25- I
( I
OH I
) I
2D3 I
receptor-positive I
T47D I
( O
human O
breast O
cancer O
) O
cells O
had O
less O
than O
10 O
% O
of O
the O
binding O
measured O
in O
T47D B
cytosol O
alone O
. O

However O
, O
the O
levels O
of O
binding O
in O
T47D B
cytosols O
were O
not O
reduced O
if O
the O
receptors O
were O
occupied O
with O
[ O
3H O
] O
-1 O
, O
25- O
( O
OH O
) O
2D3 O
prior O
to O
the O
addition O
of O
the O
CML B
cytosols O
. O

Thus O
, O
CML B
cells I
appear O
to O
contain O
both O
the O
receptor O
for O
1 O
, O
25- O
( O
OH O
) O
2D3 O
and O
an O
unknown O
substance O
which O
prevents O
its O
detection O
following O
the O
preparation O
of O
cytosol O
. O

Effect O
of O
cell O
cycle O
position O
on O
dexamethasone O
binding O
by O
mouse B
and I
human I
lymphoid I
cell I
lines I
: O
correlation O
between O
an O
increase O
in O
dexamethasone O
binding O
during O
S O
phase O
and O
dexamethasone O
sensitivity O
. O

We O
determined O
the O
effect O
of O
cell O
cycle O
position O
on O
the O
amount O
of O
dexamethasone O
that O
was O
specifically O
bound O
by O
mouse B
and I
human I
lymphoid I
cell I
lines I
. O

Cell B
lines I
that O
were O
either O
sensitive O
or O
resistant O
to O
growth O
inhibition O
by O
dexamethasone O
were O
compared O
. O

In O
three O
dexamethasone-sensitive B
cell I
lines I
( O
two O
mouse O
and O
one O
human O
) O
, O
we O
found O
that O
the O
amount O
of O
dexamethasone O
bound O
per O
cell O
increased O
2-4-fold O
between O
G1 O
phase O
and O
S O
phase O
, O
and O
then O
decreased O
during O
G2/M O
phase O
. O

In O
contrast O
, O
we O
found O
that O
the O
amount O
of O
dexamethasone O
bound O
per O
cell O
by O
three O
dexamethasone-resistant B
cell I
lines I
( O
two O
mouse O
and O
one O
human O
) O
did O
not O
increase O
during O
S O
phase O
. O

These O
included O
inhibition O
of O
the O
proliferative O
responses O
to O
the O
T-cell O
mitogens O
concanavalin O
A O
and O
phytohaemagglutinin O
and O
an O
enhanced O
accumulation O
of O
immunoglobulin O
secreting O
cells O
in O
pokeweed B
mitogen-stimulated I
cultures I
. O

An O
excess O
of O
an O
antagonist O
such O
as O
cortexolone O
was O
found O
to O
inhibit O
the O
cortisol-induced O
cytolysis O
of O
the O
CLL B
cells I
. O

It O
is O
suggested O
that O
the O
glucocorticoid-induced O
lysis O
of O
human B
CLL I
cells I
is O
similar O
to O
the O
phenomenon O
observed O
in O
rat O
or O
murine O
lymphocytes O
and O
is O
mediated O
by O
interaction O
of O
the O
steroid O
molecule O
with O
the O
cytoplasmic O
receptor O
. O

On O
the O
basis O
of O
in O
vitro O
models O
, O
it O
is O
proposed O
that O
perhaps O
the O
high B
receptor I
cell I
lines I
( O
i.e. O
, O
common O
ALL O
of O
childhood O
) O
have O
relative O
stability O
of O
their O
genetic O
material O
making O
glucocorticoid-resistant O
mutations O
less O
likely O
to O
occur O
in O
patients O
with O
these O
cells O
than O
in O
low-receptor B
cell I
lines I
( O
i.e. O
, O
T-cell O
leukemia O
) O
. O

This O
greater O
genetic O
variability O
in O
the O
low-receptor B
lines I
could O
account O
for O
the O
earlier O
emergence O
of O
clinical O
glucocorticoid O
resistance O
in O
these O
patients O
. O

Glucocorticoid O
inhibition O
of O
urokinase-like O
plasminogen O
activators O
in O
cultured B
human I
lymphoblasts I
. O

Two O
human B
lymphoblast I
cell I
lines I
, O
LICR-LON-HMy2 B
( O
HMy2 B
cells I
) O
and O
GM4672A B
cells I
, O
are O
moderately O
growth O
inhibited O
by O
dexamethasone O
( O
1 O
, O
4-pregnadien-9-fluoro-16 O
alpha-methyl-11 O
beta O
, O
17 O
alpha O
, O
21-triol-3 O
, O
20-dione O
) O
( O
Dex O
) O
. O

Treatment O
of O
both O
HMy2 B
and I
GM4672A I
cells I
with O
Dex O
for O
1-4 O
days O
inhibits O
extracellular O
PA O
activity O
in O
a O
concentration-dependent O
manner O
, O
being O
half-maximal O
at O
approximately O
1 O
X O
10 O
( O
-9 O
) O
M O
. O

HMy2 B
cell I
PA O
is O
fully O
suppressible O
by O
Dex O
, O
whereas O
up O
to O
one O
third O
of O
the O
activator O
expressed O
by O
GM4672A B
cells I
is O
resistant O
to O
glucocorticoid O
inhibition O
. O

Mixing O
experiments O
using O
a O
UK O
standard O
and O
conditioned O
media O
from O
Dex-treated B
cells I
suggest O
an O
absence O
of O
glucocorticoid-inducible O
inhibitors O
to O
UK O
or O
plasmin O
in O
both O
cell O
types O
. O

However O
, O
conditioned O
media O
from O
Dex-treated B
GM4672A I
cells I
inhibits O
a O
portion O
of O
the O
homologous O
cellular O
activator O
in O
conditioned O
media O
from O
control O
GM4672A B
cells I
. O

Glucocorticoid-inducible O
inhibitors O
in O
HMy2 B
cells I
are O
either O
totally O
absent O
or O
are O
present O
at O
undetectable O
levels O
. O

Thus O
, O
regulation O
of O
UK-like O
PAs O
in O
HMy2 B
and I
GM4672A I
cells I
differs O
with O
respect O
to O
the O
extent O
to O
which O
glucocorticoids O
inhibit O
constitutively O
expressed O
activator O
levels O
, O
as O
well O
as O
the O
possible O
contribution O
of O
glucocorticoid-inducible O
inhibitors O
to O
the O
regulatory O
process O
in O
GM4672A B
cells I
. O

Aldosterone O
binding O
sites O
in O
human B
mononuclear I
leukocytes I
were O
characterized O
after O
separation O
of O
cells O
from O
blood O
by O
a O
Percoll O
gradient O
. O

However O
, O
the O
recent O
description O
of O
estrogen O
receptors O
in O
the O
thymus O
and O
in O
some O
lymphocyte B
subpopulations I
, O
as O
well O
as O
a O
deeper O
understanding O
of O
regulating O
factors O
in O
the O
immune O
system O
, O
open O
the O
possibility O
of O
a O
more O
detailed O
understanding O
of O
the O
estrogen O
mechanism O
of O
interference O
. O

After O
treating O
neonatal O
mice O
with O
the O
synthetic O
estrogen O
diethylstilbestrol O
( O
DES O
) O
, O
disturbances O
are O
induced O
in O
lymphocyte B
populations I
and O
lymphocyte O
functions O
which O
are O
permanent O
and O
irreversible O
. O

The O
authors O
investigated O
the O
behaviour O
of O
steroid O
hormone O
uptake O
in O
leukaemic O
cells O
( O
CML B
, O
CLL B
, O
AML B
, O
ALL B
) O
, O
in O
basal O
conditions O
and O
after O
incubation O
with O
drugs O
which O
modify O
the O
cellular O
concentration O
of O
cAMP O
, O
PGE O
and O
PGF O
. O

Differences O
were O
observed O
in O
the O
behavior O
of O
hormonal O
uptake O
of O
CML B
, O
in O
contrast O
to O
that O
of O
AML B
, I
CLL I
and I
ALL I
peripheral I
leucocytes I
. O

We O
studied O
NK O
activity O
in O
patients O
with O
benign O
and O
malignant O
breast O
disease O
, O
using O
a O
chromium-51 O
release O
microtiter O
cytotoxicity O
assay O
with O
K562 B
cells I
as O
targets O
. O

The O
lymphokine O
enhanced O
the O
antimicrobial O
activity O
of O
dexamethasone-treated B
macrophages I
against O
Listeria O
and O
Salmonella O
but O
not O
against O
Aspergillus O
or O
Nocardia O
. O

Dexamethasone-induced O
damage O
to O
the O
antimicrobial O
activity O
of O
human O
macrophages O
in O
vitro O
parallels O
observations O
that O
glucocorticoids O
render O
laboratory O
animals O
susceptible O
to O
listeriosis O
and O
aspergillosis O
by O
damaging O
resident O
macrophages B
. O

Normal O
resting O
T-cells O
and O
most O
leukemic B
T-cell I
populations I
do O
not O
express O
IL-2 O
receptors O
; O
however O
, O
the O
leukemic O
cells O
of O
the O
11 O
patients O
examined O
who O
had O
human O
T-cell O
lymphotropic O
virus-associated O
adult O
T-cell O
leukemia O
expressed O
the O
Tac O
antigen O
. O

Although O
the O
specific O
binding O
further O
increased O
as O
T-cells O
entered O
the O
G1b O
phase O
( O
as O
measured O
at O
44 O
h O
of O
incubation O
and O
using O
hydroxyurea-treated B
cells I
) O
, O
the O
major O
changes O
in O
the O
specific O
binding O
of O
dexamethasone O
took O
place O
during O
the O
period O
16 O
- O
20 O
h O
after O
stimulation O
. O

Glucocorticoid O
receptors O
and O
cortico-sensitivity O
in O
a O
human B
clonal I
monocytic I
cell I
line I
, O
CM-SM B
. O

CM-SM B
is O
a O
clonal B
line I
of O
human O
precursor O
mononuclear O
phagocytes O
inducible O
to O
macrophage O
differentiation O
in O
response O
to O
the O
tumor O
promoter O
phorbol O
ester O
12-O-tetradecanoyl-phorbol-13-acetate O
( O
TPA O
) O
. O

Exposure O
of O
CM-SM B
to O
dexamethasone O
( O
DEX O
) O
produced O
a O
progressive O
, O
dose- O
and O
time-related O
series O
of O
changes O
in O
CM-SM B
cell O
growth O
, O
saturation O
density O
, O
morphology O
, O
and O
functional O
properties O
, O
with O
half-maximal O
effects O
at O
about O
10 O
( O
-9 O
) O
M O
for O
DEX O
. O

After O
5 O
days O
in O
culture O
with O
a O
saturating O
concentration O
( O
3.6 O
X O
10 O
( O
-8 O
) O
M O
) O
of O
hormone O
, O
the O
cells O
reached O
a O
saturation O
density O
of O
about O
9.0 O
X O
10 O
( O
6 O
) O
viable O
cells/ml O
( O
about O
4.0 O
X O
10 O
( O
6 O
) O
viable O
cells/ml O
in O
the O
controls O
) O
, O
while O
the O
modal O
volume O
of O
the O
resulting O
cell B
population I
was O
approximately O
60 O
% O
, O
as O
compared O
to O
the O
volume O
of O
untreated B
cells I
. O

DEX-treated B
cells I
appeared O
less O
differentiated O
than O
controls O
, O
as O
assessed O
by O
combined O
morphologic O
, O
antigenic O
, O
and O
cytoenzymatic O
analyses O
. O

Additional O
immunological O
, O
morphological O
, O
biochemical O
, O
cytokinetic O
, O
and O
cytogenetic O
factors O
have O
been O
identified O
, O
illustrating O
the O
heterogeneity O
of O
ALL O
and O
its O
derivation O
from O
malignant B
clones I
at O
various O
stages O
of O
differentiation O
and O
with O
varying O
rates O
of O
proliferation O
. O

Within O
the O
lymphoproliferative O
diseases O
, O
ALL B
cells I
exhibited O
the O
highest O
GR O
concentration O
( O
regardless O
of O
the O
method O
used O
) O
and O
the O
highest O
in O
vitro O
inhibition O
of O
spontaneous O
[ O
3H O
] O
thymidine O
( O
[ O
3H O
] O
TdR O
) O
uptake O
by O
glucocorticoids O
. O

On O
the O
contrary O
, O
CLL B
cells I
presented O
the O
highest O
sensitivity O
to O
glucocorticoids O
in O
PHA-stimulated B
cell I
cultures I
. O

CML B
cells I
exhibited O
an O
inhibition O
degree O
by O
in O
vitro O
glucocorticoids O
significantly O
higher O
than O
that O
of O
ANLL B
cells I
but O
not O
different O
from O
that O
of O
lymphoproliferative O
diseases O
. O

Glucocorticoid O
receptors O
and O
in O
vitro O
corticosensitivity O
of O
peanut-positive B
and I
peanut-negative I
human I
thymocyte I
subpopulations I
. O

Despite O
the O
greater O
number O
of O
glucocorticoid O
receptor O
sites O
, O
the O
peanut-negative B
thymocyte I
subpopulation I
did O
not O
differ O
from O
the O
peanut-positive B
one O
in O
its O
sensitivity O
to O
the O
inhibitory O
effects O
of O
triamcinolone O
acetonide O
, O
as O
determined O
by O
measurements O
of O
the O
incorporation O
of O
radiolabeled O
precursors O
of O
protein O
and O
DNA O
. O

Moreover O
, O
the O
peanut-negative B
subset I
appeared O
more O
resistant O
in O
vitro O
to O
the O
steroid-induced O
cell O
lysis O
as O
compared O
to O
the O
peanut-positive B
one O
. O

Antisera O
raised O
against O
human O
lymphoid O
glucocorticoid O
receptors O
were O
used O
in O
combination O
with O
the O
glucocorticoid O
receptor O
affinity O
label O
[ O
3H O
] O
dexamethasone O
21-mesylate O
[ O
( O
3H O
] O
DM O
) O
to O
identify O
the O
glucocorticoid O
receptors O
of O
the O
human B
B-lymphoblastoid I
cell I
line I
IM-9 B
and O
the O
human B
T-cell I
leukemic I
cell I
line I
CEM-C7 B
. O

This O
component O
was O
markedly O
diminished O
when O
cytosols O
from O
the O
glucocorticoid B
receptor-deficient I
cell I
line I
ICR-27 B
were O
used O
. O

Incubation O
of O
a O
human B
malignant I
thymus I
derived I
T I
cell I
line I
( O
MOLT B
3 I
) O
with O
TMS O
F5 O
also O
resulted O
in O
a O
significant O
reduction O
of O
the O
number O
of O
steroid O
binding O
sites O
to O
44.2 O
+/- O
15.3 O
% O
of O
control O
( O
P O
less O
than O
0.05 O
) O
, O
but O
TMS O
F5 O
did O
not O
significantly O
reduce O
the O
glucocorticoid O
sensitivity O
of O
MOLT B
3 I
cells I
. O

The O
majority O
of O
the O
infiltrating O
mononuclear O
cells O
were O
T O
cells O
; O
generally O
the O
OKT8 B
cells I
were O
predominant O
. O

To O
directly O
examine O
the O
effect O
of O
1 O
, O
25- O
( O
OH O
) O
2D3 O
on O
T O
cell O
activation O
in O
the O
absence O
of O
other O
complicating O
interactions O
, O
we O
utilized O
a O
panel O
of O
cloned O
Ia-restricted B
T I
cell I
hybridomas I
that O
secrete O
IL O
2 O
on O
activation O
by O
cloned O
Ia-bearing O
stimulator O
cells O
( O
TA3 O
) O
or O
when O
stimulated O
by O
mitogen O
. O

Physiologic O
concentrations O
of O
1 O
, O
25- O
( O
OH O
) O
2D3 O
( O
0.01 O
to O
0.1 O
nm O
) O
inhibited O
the O
antigen-induced O
secretion O
of O
IL O
2 O
by O
several O
of O
these O
T B
cell I
hybridomas I
. O

This O
inhibition O
was O
dependent O
on O
the O
concentration O
of O
the O
free O
hormone O
and O
could O
be O
overcome O
by O
increasing O
the O
number O
of O
Ia-bearing B
stimulator I
cells I
used O
. O

Pretreatment O
of O
the O
T B
hybridoma I
but O
not O
the O
TA3 B
stimulator I
cell I
with O
1 O
, O
25- O
( O
OH O
) O
2D3 O
resulted O
in O
inhibition O
of O
activation O
. O

These O
results O
are O
consistent O
with O
the O
finding O
that O
specific O
1 O
, O
25- O
( O
OH O
) O
2D3 O
receptors O
are O
present O
on O
the O
T O
cell O
hybridomas O
but O
are O
lacking O
in O
TA3 B
cells I
. O

1 O
, O
25- O
( O
OH O
) O
2D3 O
failed O
, O
however O
, O
to O
inhibit O
the O
activation O
of O
the O
T B
cell I
hybridomas I
by O
lectin O
or O
by O
an O
anti-Thy-1 O
antibody O
. O

To O
assess O
the O
interaction O
between O
these O
atypical O
steroids O
and O
the O
glucocorticoid O
receptor O
, O
we O
examined O
the O
binding O
of O
[ O
3H O
] O
CVZ O
to O
cytosol O
from O
glucocorticoid-sensitive B
and I
-resistant I
variants I
of O
the O
human B
leukemic I
cell I
line I
CEM B
C7 I
. O

In O
glucocorticoid-sensitive B
cells I
[ O
3H O
] O
CVZ O
causes O
a O
2-fold O
induction O
of O
glutamine O
synthetase O
and O
binds O
to O
a O
protein O
in O
the O
4.6 O
S O
region O
of O
high O
salt O
sucrose O
gradients O
. O

Scatchard O
analysis O
of O
the O
binding O
of O
[ O
3H O
] O
CVZ O
in O
glucocorticoid-sensitive B
cells I
revealed O
a O
curvilinear O
plot O
which O
resolved O
into O
high O
( O
0.4 O
nM O
) O
and O
low O
( O
11 O
nM O
) O
affinity O
components O
. O

In O
cytosol O
from O
a O
glucocorticoid-resistant B
cell I
line I
with O
virtually O
no O
[ O
3H O
] O
DEX O
binding O
, O
[ O
3H O
] O
CVZ O
detected O
a O
single O
high O
affinity O
binding O
site O
that O
was O
similar O
in O
dissociation O
constant O
( O
0.8 O
nM O
) O
and O
receptor O
concentration O
( O
0.13 O
pmol/mg O
protein O
) O
to O
the O
high O
affinity O
site O
detected O
in O
the O
glucocorticoid-sensitive B
cell I
line I
C7 B
. O

Agarose O
filtration O
and O
ultracentrifugation O
in O
hypotonic O
buffers O
containing O
20 O
mM O
Na2MoO4 O
revealed O
complexes O
of O
similar O
size O
and O
shape O
in O
all O
clinical O
specimens O
tested O
and O
two O
established O
leukemic B
cell I
lines I
. O

Human B
lymphoid I
cell I
lines I
and O
glucocorticoids O
: O
II O
. O

Whole O
cell O
and O
cytoplasmic O
binding O
properties O
of O
lymphoblastoid B
, I
leukaemia I
and I
lymphoma I
lines I
. O

The O
glucocorticoid O
binding O
properties O
of O
18 O
human B
lymphoid I
cell I
lines I
( O
HLCL B
) O
have O
been O
investigated O
. O

A O
gradation O
in O
whole O
cell O
and O
cytoplasmic O
glucocorticoid O
binding O
capacity O
was O
observed O
in O
the O
different O
cell O
line O
types O
: O
lymphoblastoid B
greater O
than O
lymphoma B
greater O
than O
leukaemia B
. O

The O
cytoplasmic O
receptors O
of O
leukaemia B
and I
lymphoblastoid I
lines I
appeared O
to O
contain O
both O
proteinaceous O
and O
phospholipid O
components O
. O

No O
correlation O
was O
observed O
between O
the O
level O
or O
nature O
of O
glucocorticoid O
binding O
and O
the O
cytolethal O
or O
cytostatic O
responsiveness O
of O
HLCL B
to O
glucocorticoid O
treatment O
in O
vitro O
. O

Ikaros O
in O
hemopoietic B
lineage I
determination O
and O
homeostasis O
. O

Overexpression O
of O
Rel O
proteins O
demonstrated O
that O
p65-expressing B
Jurkat I
cells I
transcribed O
equally O
well O
a O
nuclear O
factor O
kappabeta O
reporter O
construct O
when O
costimulated O
with O
B7-1 O
or O
LFA-3 O
, O
but O
transcription O
of O
IL-2 O
promoter O
or O
CD28 O
response O
element O
( O
CD28RE O
) O
-driven O
reporters O
was O
superior O
in O
B7-1-costimulated B
cells I
. O

HIV-1 O
infection O
of O
primary O
monocytic O
cells O
and O
myeloid B
cell I
lines I
results O
in O
sustained O
NF-kappaB O
activation O
. O

In O
the O
present O
study O
, O
we O
sought O
to O
investigate O
whether O
constitutive O
NF-kappaB O
activity O
in O
chronically O
HIV-1-infected O
promonocytic B
U937 I
( I
U9-IIIB I
) I
and I
myeloblastic I
PLB-985 I
( I
PLB-IIIB I
) I
cells I
affects O
apoptotic O
signaling O
. O

TNFalpha O
and O
cycloheximide O
caused O
infected O
cells O
to O
undergo O
apoptosis O
more O
rapidly O
than O
parental B
U937 I
and O
PLB-985 B
cells I
. O

Inhibition O
of O
TNFalpha O
-induced O
NF-kappaB O
activation O
using O
the O
antioxidant O
N-acetylcysteine O
( O
NAC O
) O
resulted O
in O
increased O
apoptosis O
in O
both O
U937 B
and I
U9-IIIB I
cells I
, O
while O
preactivation O
of O
NF-kappaB O
with O
the O
non-apoptotic O
inducer O
IL-1beta O
caused O
a O
relative O
decrease O
in O
apoptosis O
. O

Inhibition O
of O
constitutive O
NF-kappaB O
activity O
in O
U9-IIIB B
and I
PLB-IIIB I
cells I
also O
induced O
apoptosis O
, O
suggesting O
that O
NF-kappaB O
protects O
cells O
from O
a O
persistent O
apoptotic O
signal O
. O

The O
protective O
role O
of O
NF-kappaB O
in O
blocking O
TNFalpha- O
and O
HIV-1-induced O
apoptosis O
was O
supported O
by O
studies O
in O
Jurkat B
T I
cells I
engineered O
to O
express O
IkappaB O
alpha O
repressor O
mutants O
( O
TD-IkappaB O
) O
under O
the O
control O
of O
a O
tetracycline-responsive O
promoter O
. O

As O
was O
observed O
for O
the O
U9-IIIB B
cells I
, O
TNFalpha O
treatment O
also O
induced O
a O
marked O
decrease O
in O
Bcl-2 O
protein O
levels O
in O
TD-IkappaB O
expressing O
cells O
. O

These O
experiments O
demonstrate O
that O
apoptotic O
signaling O
is O
perturbed O
in O
HIV-1-infected O
U9-IIIB B
cells I
and O
indicate O
that O
NF-kappaB O
activation O
may O
play O
an O
additional O
protective O
role O
against O
HIV-1-induced O
apoptosis O
in O
myeloid O
cells O
. O

The O
absence O
of O
P-CREB O
following O
CD3 O
cross-linking O
was O
unexpected O
, O
as O
other O
laboratories O
reported O
increased O
phosphorylation O
of O
CREB O
following O
CD3 O
cross-linking O
of O
the O
Jurkat B
lymphocyte I
cell I
line I
. O

Due O
to O
Jurkat B
T-cells I
being O
IL-2-independent O
, O
it O
was O
postulated O
that O
IL-2 O
might O
provide O
a O
necessary O
co-stimulus O
for O
phosphorylation O
of O
CREB O
in O
primary O
lymphocytes O
. O

Here O
we O
show O
that O
forced O
expression O
of O
the O
lung O
Kruppel-like O
transcription O
factor O
( O
LKLF O
) O
in O
Jurkat B
T I
cells I
is O
sufficient O
to O
program O
a O
quiescent O
phenotype O
characterized O
by O
decreased O
proliferation O
, O
reduced O
cell O
size O
and O
protein O
synthesis O
and O
decreased O
surface O
expression O
of O
activation O
markers O
. O

Transduction O
of O
primary B
human I
peripheral I
blood I
mononuclear I
cells I
( O
PBMCs O
) O
with O
a O
human O
immunodeficiency O
virus O
type O
1-based O
retroviral O
vector O
expressing O
p12 O
( O
I O
) O
also O
resulted O
in O
increased O
STAT5 O
phosphorylation O
and O
DNA O
binding O
. O

TRAF2 O
-mediated O
NF-kappaB O
activation O
, O
AP-1 O
induction O
and O
JAK3 O
/ O
STAT O
activation O
may O
result O
in O
sustained O
proliferation O
leading O
to O
lymphoma B
. O

Cytotoxic O
T O
lymphocytes O
directed O
against O
well-characterized O
epitopes O
of O
EBV O
latency O
genes O
represent O
an O
already O
successful O
and O
promising O
therapeutic O
approach O
to O
EBV-associated B
lymphomas I
, O
in O
particular O
PTLDs O

Activation O
of O
the O
p21 O
( O
CIP1/WAF1 O
) O
promoter O
by O
bone O
morphogenetic O
protein-2 O
in O
mouse O
B B
lineage I
cells I
. O

We O
have O
previously O
reported O
that O
BMP-2 O
inhibited O
the O
growth O
of O
HS-72 B
mouse I
hybridoma I
cells I
by O
inducing O
p21 O
( O
CIP1/WAF1 O
) O
expression O
. O

In O
the O
present O
study O
, O
we O
demonstrated O
that O
BMP-2 O
activated O
the O
mouse O
p21 O
( O
CIP1/WAF1 O
) O
promoter O
in O
HS-72 B
cells I
, O
and O
that O
a O
29-base O
pair O
( O
b O
) O
region O
of O
the O
promoter O
( O
-1928/-1900 O
relative O
to O
the O
TATA O
box O
) O
, O
conserved O
between O
mice O
and O
humans O
, O
was O
responsive O
to O
BMP-2 O
as O
well O
as O
expression O
of O
Smad1 O
, O
Smad4 O
, O
and O
constitutively O
active O
mutants O
of O
BMP O
type O
I O
receptors O
. O

Furthermore O
, O
an O
oligonucleotide O
containing O
the O
29-b O
region O
was O
found O
to O
be O
associated O
with O
Smad4 O
and O
phosphorylated O
Smad1 O
in O
the O
nuclear O
extract O
of O
BMP-2 O
-stimulated O
HS-72 B
cells I
. O

These O
results O
suggested O
that O
BMP-2 O
might O
activate O
p21 O
( O
CIP1/WAF1 O
) O
transcription O
by O
inducing O
a O
binding O
of O
Smad4 O
and O
Smad1 O
to O
the O
29-b O
region O
in O
HS-72 B
cells I
. O

Using O
MonoMac6 B
cells I
, O
we O
observed O
high O
C/EBPbeta O
and O
AP-1 O
but O
weaker O
and O
transient O
NF-kappaB O
activation O
by O
MB O
. O

Moreover O
, O
the O
truncated O
form O
of O
C/EBPbeta O
, O
known O
to O
repress O
HIV-1 O
transcription O
, O
was O
detected O
in O
extracts O
from O
MB-treated B
THP-1 I
cells I
. O

We O
identified O
PPAR-alpha O
and O
-gamma O
messenger O
RNA O
by O
RT-PCR O
and O
protein O
by O
immunoblotting O
of O
lysates O
of O
peritoneal O
macrophages O
and O
monocytic B
U937 I
cells I
. O

Migration O
of O
U937 B
cells I
was O
increased O
by O
WY O
14643 O
and O
reduced O
by O
rosiglitazone O
. O

Peritoneal O
fluid O
from O
patients O
with O
endometriosis O
activated O
U937 B
cells I
transiently O
transfected O
with O
a O
PPAR-alpha/GAL4 O
luciferase O
reporter O
. O

The O
U937 B
cells I
transiently O
transfected O
with O
a O
PPAR O
response O
element O
luciferase O
reporter O
showed O
disease O
stage-dependent O
up-regulation O
when O
treated O
with O
peritoneal O
fluid O
from O
patients O
with O
endometriosis O
. O

These O
results O
indicate O
that O
the O
fly O
and O
mouse O
FOG O
proteins O
function O
similarly O
in O
three O
distinct O
cellular O
contexts O
in O
Drosophila O
, O
but O
may O
use O
different O
mechanisms O
to O
regulate O
genetic O
events O
in O
blood O
vs O
. O
cardial B
or I
eye I
cell I
lineages I

TRAIL/Apo2L O
potently O
induced O
apoptosis O
of O
MM O
cells O
from O
patients O
and O
the O
majority O
of O
MM B
cell I
lines I
, O
including O
cells O
sensitive O
or O
resistant O
to O
dexamethasone O
( O
Dex O
) O
, O
doxorubicin O
( O
Dox O
) O
, O
melphalan O
, O
and O
mitoxantrone O
. O

Constitutive O
expression O
of O
MHC O
class O
II O
genes O
in O
melanoma B
cell I
lines I
results O
from O
the O
transcription O
of O
class O
II O
transactivator O
abnormally O
initiated O
from O
its O
B O
cell-specific O
promoter O
. O

In O
melanoma B
cell I
lines I
, O
two O
different O
patterns O
of O
MHC O
class O
II O
expression O
have O
been O
described O
, O
either O
an O
IFN O
gamma-inducible O
expression O
of O
HLA-DR O
and O
HLA-DP O
, O
with O
a O
faint O
or O
null O
expression O
of O
HLA-DQ O
, O
resembling O
that O
described O
for O
melanocytes O
, O
or O
a O
constitutive O
expression O
, O
i.e. O
, O
IFN-gamma O
independent O
, O
of O
all O
three O
HLA-D O
isotypes O
. O

As O
this O
latter O
phenotype O
has O
been O
associated O
with O
a O
more O
rapid O
progression O
of O
melanoma O
tumors O
, O
we O
have O
analyzed O
in O
different O
melanoma B
cell I
lines I
the O
molecular O
mechanisms O
leading O
to O
this O
abnormal O
pattern O
of O
MHC O
class O
II O
expression O
. O

Constitutive O
transcription O
of O
CIITA O
from O
promoter O
III O
having O
been O
observed O
in O
unrelated O
melanoma B
cell I
lines I
, O
we O
propose O
the O
hypothesis O
that O
this O
phenomenon O
might O
not O
be O
a O
random O
event O
, O
but O
could O
be O
linked O
to O
the O
neoplasic O
state O
of O
the O
melanoma O
cells O

It O
has O
been O
previously O
reported O
that O
IL-2 O
release O
in O
activated O
Jurkat B
T I
requires O
caspase-like O
activity O
( O
Posmantur O
et O
al. O
( O
1998 O
) O
Exp. O
Cell. O
Res. O
244 O
, O
302-309 O
) O
. O

We O
report O
here O
that O
the O
60-kDa O
catalytic O
subunit O
of O
calcineurin O
A O
( O
Cn O
A O
) O
was O
partially O
cleaved O
to O
a O
45-kDa O
form O
in O
phytohemagglutinin O
A O
( O
PHA O
) O
or O
phorbol O
ester O
+ O
ionomycin O
( O
P O
+ O
I O
) O
-activated O
Jurkat B
cells I
. O

Furthermore O
, O
in O
PHA O
or O
P O
+ O
I-activated O
Jurkat B
cells I
, O
dephosphorylation O
of O
calcineurin O
substrate O
NFATc O
( O
a O
transcription O
factor O
known O
to O
be O
involved O
in O
transactivation O
of O
the O
IL-2 O
gene O
) O
, O
was O
also O
suppressed O
by O
Z-D-DCB O
. O

A O
specific O
proteasome O
defect O
has O
been O
identified O
in O
NOD O
mouse O
in O
select O
lymphocytic B
and I
monocytic I
lineages I
that O
results O
from O
down-regulation O
of O
expression O
of O
the O
proteasome O
subunit O
LMP2 O
, O
which O
is O
encoded O
by O
a O
gene O
in O
the O
MHC O
genomic O
region O
. O

Mutations O
that O
selectively O
disrupt O
Ikaros O
binding O
to O
an O
integrated O
TdT O
promoter O
had O
no O
effect O
on O
promoter O
function O
in O
a O
CD4 B
( I
+ I
) I
CD8 I
( I
+ I
) I
thymocyte I
line I
. O

Surprisingly O
, O
in O
the O
CD4 B
( I
+ I
) I
CD8 I
( I
+ I
) I
thymocyte I
line I
, O
overexpression O
of O
a O
small O
Ikaros O
isoform O
had O
no O
effect O
on O
differentiation O
or O
on O
the O
pericentromeric O
targeting O
and O
DNA-binding O
properties O
of O
Ikaros O
. O

To O
investigate O
the O
role O
of O
costimulation O
of O
OX40 O
in O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV-1 O
) O
infection O
by O
its O
natural O
ligand O
, O
gp34 O
, O
the O
OX40-transfected B
ACH-2 I
cell I
line I
, I
ACH-2/OX40 I
, O
chronically O
infected O
with O
HIV-1 O
, O
was O
cocultured O
with O
paraformaldehyde O
( O
PFA O
) O
-fixed O
gp34-transfected B
mouse I
cell I
line I
, I
SV-T2/gp34 I
. O

Furthermore O
, O
enhanced O
HIV-1 O
transcription O
in O
gp34 O
-stimulated O
ACH-2/OX40 B
cells I
was O
dependent O
on O
the O
kappa O
B O
site O
of O
the O
HIV-1 O
long O
terminal O
repeat O
, O
and O
the O
OX40-gp34 O
interaction O
activated O
NF-kappa O
B O
consisting O
of O
p50 O
and O
p65 O
subunits O
. O

When O
primary O
activated O
CD4 O
( O
+ O
) O
T O
cells O
acutely O
infected O
with O
HIV-1 O
( O
NL4-3 O
) O
( O
CXCR4-using B
T-cell-line-tropic I
) O
were O
cocultured O
with O
PFA-fixed O
gp34 O
( O
+ O
) O
human O
T-cell O
leukemia O
virus O
type O
1-bearing O
MT-2 B
cells I
or O
SV-T2/gp34 B
cells I
, O
HIV-1 O
production O
was O
also O
markedly O
enhanced O
. O

In O
this O
study O
, O
we O
examined O
whether O
PPARgamma O
ligand O
regulates O
osteopontin O
gene O
expression O
in O
THP-1 B
cells I
, O
a O
cell O
line O
derived O
from O
human O
monocytic O
leukemia O
cells O
which O
can O
differentiate O
to O
macrophage O
upon O
stimulation O
with O
phorbol O
ester O
PMA O
. O

RESULTS O
: O
TPO O
enhanced O
the O
proliferation O
of O
Mo-7e B
cells I
as O
determined O
by O
3H-thymidine O
incorporation O
, O
whereas O
TGF-beta1 O
suppressed O
baseline O
cell O
growth O
and O
antagonized O
the O
proliferative O
effect O
of O
TPO O
. O

As O
demonstrated O
by O
Western O
blotting O
, O
TGF-beta1 O
reduced O
the O
TPO O
-stimulated O
ERK1 O
/ O
ERK2 O
and O
STAT5 O
phosphorylation O
in O
Mo-7e B
and I
HEL I
cells I
. O

We O
have O
identified O
a O
functional O
AP-1 O
site O
that O
lies O
between O
( O
-106 O
to O
-100 O
) O
through O
transient O
transfection O
analysis O
in O
YT B
cells I
, O
a O
human B
NK I
cell I
line I
. O

Multipotent O
HSCs O
become O
committed O
to O
the O
B B
cell I
lineage I
in O
bone O
marrow O
and O
the O
T B
cell I
lineage I
in O
the O
thymus O
after O
receiving O
appropriate O
signals O
from O
the O
corresponding O
microenvironment O
. O

Indeed O
, O
transient O
expression O
of O
GILZ O
in O
Jurkat B
T I
cells I
blocked O
induction O
of O
a O
reporter O
construct O
driven O
by O
the O
FasL O
promoter O
. O

First O
, O
we O
found O
that O
TGF-beta1 O
significantly O
increases O
endogenous O
germ-line O
( O
GL O
) O
alpha O
transcripts O
by O
LPS-stimulated O
CH12.LX.4933 B
( I
mu I
( I
+ I
) I
) I
B I
lymphoma I
cells I
. O

To O
investigate O
its O
signaling O
mechanisms O
, O
the O
lymphoma B
cell I
line I
was O
transfected O
with O
pFL3 O
that O
contains O
the O
TGF-beta-responsive O
element O
of O
the O
GLalpha O
promoter O
, O
and O
stimulated O
with O
TGF-beta1 O
. O

We O
previously O
reported O
that O
Tax O
induced O
cell O
cycle O
progression O
from O
G0/G1 O
phase O
to O
S O
and O
G2/M O
phases O
in O
human B
T-cell I
line I
Kit I
225 I
cells I
. O

Introduction O
of O
Tax O
into O
resting B
Kit I
225 I
cells I
induced O
activation O
of O
the O
G1/S O
transition O
regulation O
cascade O
consisting O
of O
activation O
of O
cyclin O
dependent O
kinase O
2 O
( O
CDK2 O
) O
and O
CDK4 O
, O
phosphorylation O
of O
the O
Rb O
family O
proteins O
and O
an O
increase O
in O
free O
E2F O
. O

Here O
we O
report O
that O
Cot O
kinase O
, O
a O
mitogen-activated O
protein O
kinase O
kinase O
kinase O
involved O
in O
T O
cell O
activation O
, O
up-regulates O
COX-2 O
gene O
expression O
in O
Jurkat B
T I
cells I
. O

Mutation O
of O
either O
Tyr248 O
, O
Tyr357 O
, O
or O
Tyr462 O
to O
phenylalanine O
reduced O
transcription O
from O
a O
c-fos O
promoter O
relative O
to O
wild-type O
BAP/TFII-I O
in O
transfected O
COS-7 B
cells I
, O
consistent O
with O
the O
interpretation O
that O
phosphorylation O
at O
these O
sites O
contributes O
to O
transcriptional O
activation O
. O

To O
evaluate O
transcriptional O
regulation O
of O
the O
IL-2 O
gene O
in O
CD8+ O
T O
cells O
, O
we O
stably O
transfected O
reporter O
genes O
into O
Ag O
-specific O
CD8+ B
T I
cell I
clones I
. O

Stem O
cell O
factor O
and O
interleukin-3 O
induce O
stepwise O
generation O
of O
erythroid O
precursor O
cells O
from O
a O
basic O
fibroblast O
growth O
factor O
-dependent O
hematopoietic B
stem I
cell I
line I
, I
A-6 I
. O

A O
m O
ultipotent O
immature O
myeloid O
cell O
population O
was O
produced O
from O
a O
basic O
fibroblast O
growth O
factor O
( O
bFGF O
) O
-dependent O
hematopoietic B
stem I
cell I
line I
, I
A-6 I
, O
when O
cultured O
with O
stem O
cell O
factor O
( O
SCF O
) O
replacing O
bFGF O
. O

SCF O
and O
IL-3 O
induced O
stepwise O
generation O
of O
erythroid O
precursor O
cells O
from O
an O
A-6 B
hematopoietic I
stem I
cell I
line I
. O

Expression O
of O
the O
Gads O
cleavage O
products O
in O
Jurkat B
T I
cells I
inhibited O
NFAT O
activation O
following O
TCR O
cross O
linking O
. O

In O
contrast O
, O
the O
CBFbeta O
- O
smooth O
muscle O
myosin O
heavy O
chain O
( O
SMMHC O
) O
fusion O
protein O
generated O
by O
the O
inv O
( O
16 O
) O
associated O
with O
acute B
myeloid I
leukemias I
( O
M4Eo B
) O
can O
not O
rescue O
definitive O
hematopoiesis O
by O
Cbfb-deficient O
ES O
cells O
. O

The O
expression O
of O
EBV-related O
antigens O
was O
examined O
by O
immunostaining O
using O
paraffin-embedded O
tissue O
sections O
and O
cell O
pellets O
of O
EBV-positive B
cell I
lines I
. O

Our O
study O
demonstrated O
that O
all O
samples O
from O
the O
patients O
contained O
EBV O
nuclear O
antigen O
( O
EBNA O
) O
-1 O
mRNA O
which O
was O
transcribed O
using O
the O
Q O
promoter O
, O
whereas O
both O
the O
Q O
promoter O
and O
another O
upstream O
promoter O
( O
Cp/Wp O
) O
were O
used O
in O
EBV-positive B
cell I
lines I
, O
B95.8 B
, O
Raji B
and O
Jiyoye B
. O

Latent O
membrane O
protein-1 O
( O
LMP-1 O
) O
mRNA O
was O
detected O
in O
seven O
of O
eight O
patients O
and O
all O
cell B
lines I
, O
whereas O
EBNA-2 O
transcripts O
were O
found O
only O
in O
the O
cell B
lines I
. O

Immunostaining O
showed O
no O
LMP-1 O
, O
EBNA-2 O
or O
ZEBRA O
antigens O
in O
the O
paraffin-embedded O
tissue O
sections O
, O
although O
they O
were O
positive O
in O
the O
cell B
line I
cells I
. O

PU.1 O
is O
a O
member O
of O
the O
Ets O
family O
of O
transcription O
factors O
required O
for O
the O
development O
of O
various O
lymphoid B
and I
myeloid I
cell I
lineages I
, O
but O
its O
role O
in O
natural O
killer O
( O
NK O
) O
cell O
development O
is O
not O
known O
. O

To O
better O
understand O
the O
mechanisms O
of O
their O
proinflammatory O
activities O
, O
we O
studied O
the O
effects O
of O
several O
components O
extracted O
from O
DEPs O
on O
interleukin O
( O
IL O
) O
-8 O
expression O
in O
human B
bronchial I
epithelial I
cell I
line I
BEAS-2B I
and O
normal O
human O
airway O
epithelial O
cells O
obtained O
from O
very O
peripheral O
airways O
by O
an O
ultrathin O
bronchoscope O
. O

Notch1 O
also O
inhibited O
TCR-mediated O
signaling O
in O
Jurkat B
T I
cells I
. O

The O
SART3 O
antigen O
was O
detected O
in O
all O
of O
the O
breast B
cancer I
cell I
lines I
tested O
, O
30 O
of O
40 O
( O
75 O
% O
) O
breast O
cancer O
tissue O
samples O
, O
and O
0 O
of O
3 O
non-tumourous O
breast O
tissue O
samples O
. O

Culture O
with O
the O
murine B
fetal I
liver I
cell I
line I
AFT024 I
and O
defined O
cytokines O
was O
capable O
of O
inducing O
TCF-1 O
mRNA O
. O

To O
determine O
the O
presence O
and O
potential O
role O
of O
BCL-6 O
mutations O
in O
cHD O
, O
the O
5'-noncoding O
BCL-6 O
proportion O
of O
single O
Hodgkin O
and O
Reed-Sternberg O
( O
HRS O
) O
cells O
from O
6 O
cases O
of O
cHD O
and O
6 O
cases O
of O
HD-derived B
cell I
lines I
was O
analyzed O
. O

Investigation O
of O
mast O
cell O
responsiveness O
toward O
retinoic O
acid O
( O
RA O
) O
revealed O
selective O
promotion O
of O
ICAM-3 O
expression O
in O
the O
human B
mast I
cell I
line I
HMC-1 I
. O

ICAM-3 O
modulation O
was O
found O
to O
be O
cell-type O
dependent O
, O
detectable O
also O
for O
HL-60 B
cells I
and O
monocytes O
but O
not O
U-937 B
and O
only O
weakly O
for O
KU812 B
cells I
. O

Investigation O
of O
retinoid O
receptor O
expression O
, O
known O
to O
mediate O
intracellular O
RA O
signaling O
, O
revealed O
presence O
of O
RAR O
alpha O
, O
RAR O
gamma O
, O
RXR O
beta O
, O
and O
RXR O
gamma O
transcripts O
in O
all O
cell O
lines O
studied O
, O
and O
HMC-1 B
cells I
were O
the O
only O
line O
lacking O
RXR O
alpha O
. O

ER-27191 O
completely O
antagonized O
HL60 B
cell I
differentiation O
induced O
by O
all-trans-retinoic O
acid O
( O
atRA O
) O
. O

During O
HL60 B
cell I
differentiation O
, O
atRA O
induced O
RARbeta O
mRNA O
, O
while O
the O
RXR O
had O
no O
effect O
. O

In O
Jurkat B
T I
cells I
, O
approximately O
5 O
-- O
10 O
% O
of O
Src O
homology O
2 O
domain-containing O
tyrosine O
phosphatase O
( O
SHP-1 O
) O
is O
constitutively O
associated O
with O
plasma O
membrane O
, O
and O
nearly O
50 O
% O
of O
SHP-2 O
is O
translocated O
to O
plasma O
membrane O
after O
vanadate O
treatment O
. O

SDF1 O
alpha O
treatment O
of O
Jurkat B
T I
cells I
increased O
the O
activity O
of O
NO O
synthase O
, O
which O
catalyzes O
the O
generation O
of O
NO O
. O

We O
observed O
that O
pretreatment O
of O
Jurkat B
cells I
or O
activated O
PBLs O
with O
several O
NO O
donors O
significantly O
enhanced O
the O
SDF1 O
alpha O
-induced O
migration O
, O
whereas O
various O
inhibitors O
of O
NO O
synthase O
markedly O
abrogated O
the O
chemotactic O
response O
in O
a O
concentration-dependent O
manner O
. O

To O
examine O
whether O
Epstein-Barr O
virus O
( O
EBV O
) O
lytic O
replication O
interferes O
with O
PML O
bodies O
, O
we O
expressed O
the O
EBV O
immediate-early O
genes O
BZLF1 O
( O
Z O
) O
and O
BRLF1 O
( O
R O
) O
in O
EBV-positive B
cell I
lines I
and O
examined O
PML O
localization O
. O

Z O
but O
not O
R O
expression O
is O
sufficient O
to O
disrupt O
PML O
bodies O
in O
EBV-negative B
cell I
lines I
. O

The O
involvement O
of O
the O
tyrosine O
kinases O
p56 O
( O
lck O
) O
and O
ZAP-70 O
in O
this O
reaction O
is O
demonstrated O
here O
using O
specific O
pharmacological O
inhibitors O
and O
Jurkat B
mutants I
unable O
to O
express O
these O
kinases O
. O

Although O
the O
inhibitors O
prevented O
both O
pervanadate-induced O
phosphorylation O
of O
I O
kappa O
B-alpha O
on O
Tyr42 O
and O
NF-kappa O
B O
activation O
, O
we O
observed O
that O
, O
in O
p56 B
( I
lck I
) I
-deficient I
Jurkat I
mutants I
, O
NF-kappa O
B O
could O
still O
associate O
with O
I O
kappa O
B-alpha O
despite O
phosphorylation O
on O
Tyr42 O
. O

However O
, O
ATRA O
metabolism O
appears O
to O
be O
involved O
in O
the O
growth O
inhibition O
of O
several O
cancer B
cell I
lines I
in O
vitro O
. O

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
in O
vitro O
activity O
of O
the O
principal O
metabolites O
of O
ATRA O
[ O
4-hydroxy-retinoic O
acid O
( O
4-OH-RA O
) O
, O
18-hydroxy-retinoic O
acid O
( O
18-OH-RA O
) O
, O
4-oxo-retinoic O
acid O
( O
4-oxo-RA O
) O
, O
and O
5 O
, O
6-epoxy-retinoic O
acid O
( O
5 O
, O
6-epoxy-RA O
) O
] O
in O
NB4 B
, I
a I
human I
promyelocytic I
leukemia I
cell I
line I
that O
exhibits O
the O
APL O
diagnostic O
t O
( O
15 O
; O
17 O
) O
chromosomal O
translocation O
and O
expresses O
the O
PML-RAR O
alpha O
fusion O
protein O
. O

We O
established O
that O
the O
four O
ATRA O
metabolites O
were O
indeed O
formed O
by O
the O
NB4 B
cells I
in O
vitro O
. O

ATRA O
and O
its O
metabolites O
could O
induce O
NB4 B
cells I
differentiation O
with O
similar O
activity O
, O
as O
evaluated O
by O
cell O
morphology O
, O
by O
the O
nitroblue O
tetrazolium O
reduction O
test O
( O
82-88 O
% O
at O
120 O
h O
) O
or O
by O
the O
expression O
of O
the O
maturation O
specific O
cell O
surface O
marker O
CD11c O
. O

The O
ATRA O
metabolites O
were O
found O
to O
exert O
their O
differentiation O
effects O
via O
the O
RAR O
alpha O
nuclear O
receptors O
, O
because O
the O
RAR O
alpha-specific O
antagonist O
BMS614 O
blocked O
metabolite-induced O
CD11c O
expression O
in O
NB4 B
cells I
. O

In O
the O
present O
study O
we O
found O
that O
DMA-2 O
, O
4-D O
is O
able O
to O
cause O
apoptosis O
in O
peripheral O
blood O
lymphocytes O
of O
healthy O
individuals O
and O
Jurkat B
T I
cells I
. O

Transfection O
of O
Jurkat B
cells I
with O
Bcl-2 O
prevented O
DMA-2 O
, O
4-D-induced O
disruption O
of O
the O
mitochondrial O
transmembrane O
potential O
and O
led O
to O
a O
complete O
blockage O
of O
apoptosis O
. O

ASA O
inhibited O
IL-4 O
, O
but O
not O
IL-2 O
, O
promoter-driven O
chloramphenicol O
acetyltransferase O
expression O
in O
transiently O
transfected O
Jurkat B
T I
cells I
. O

Neither O
full-length O
isoform O
alters O
growth O
of O
a O
myeloid B
cell I
line I
under O
nondifferentiating O
conditions O
, O
but O
the O
proximal O
isoform O
selectively O
delays O
mitotic O
arrest O
of O
the O
cell O
line O
under O
differentiating O
conditions O
, O
resulting O
in O
the O
generation O
of O
greater O
numbers O
of O
neutrophils O
. O

In O
the O
present O
study O
we O
show O
that O
the O
ubiquitously O
expressed O
transcription O
factor O
AP-4 O
, O
and O
not O
E47 O
, O
interacts O
specifically O
with O
the O
kappa O
promoter O
E-boxes O
when O
tested O
in O
electrophoretic O
mobility-shift O
assays O
using O
nuclear O
extracts O
derived O
from O
human B
and I
murine I
B-cell I
lines I
. O

This O
peptide O
induced O
CTL O
in O
C57BL/6 O
mice O
and O
protected O
them O
against O
growth O
of O
an O
ovalbumin B
expressing I
tumour I
cell I
line I
( O
E.G7-OVA B
) O
. O

The O
in O
vitro O
effect O
of O
G-CSF O
and O
corticosteroids O
on O
granulopoiesis O
was O
evaluated O
in O
clonogenic O
assays O
of O
marrow O
mononuclear O
cells O
, O
by O
proliferation O
studies O
of O
the O
murine B
myeloid I
cell I
line I
32D I
expressing O
the O
patient O
's O
mutated O
G-CSFR O
, O
and O
by O
measuring O
STAT5 O
activation O
in O
nuclear O
extracts O
from O
stimulated O
cells O
. O

Proliferation O
of O
32D B
cells I
expressing O
the O
mutated O
receptor O
and O
STAT5 O
activation O
were O
improved O
by O
a O
combination O
of O
G-CSF O
and O
dexamethasone O
. O

We O
have O
studied O
in O
cultured B
human I
mesangial I
cells I
( O
CHMC B
) O
several O
effects O
of O
9-cis O
retinoic O
acid O
( O
9-cRA O
) O
, O
an O
activator O
of O
both O
retinoic O
acid O
receptors O
( O
RARs O
) O
and O
retinoid O
X O
receptors O
( O
RXRs O
) O
. O

9-cRA O
inhibited O
foetal O
calf O
serum-induced O
CHMC B
proliferation O
. O

It O
also O
prevented O
CHMC B
death O
induced O
by O
the O
inflammatory O
mediator O
H O
( O
2 O
) O
O O
( O
2 O
) O
. O

Finally O
, O
9-cRA O
diminished O
monocyte O
adhesion O
to O
FCS-stimulated B
CHMC I
. O

All O
major O
RARs O
and O
RXRs O
isotypes O
were O
expressed O
in O
CHMC B
regardless O
of O
the O
presence O
or O
absence O
of O
9-cRA O
. O

To O
monitor O
changes O
in O
the O
subcellular O
distribution O
of O
Syk O
in O
B O
cells O
responding O
to O
BCR O
cross-linking O
, O
we O
expressed O
in O
Syk O
-deficient O
DT40 B
B I
cells I
a O
fusion O
protein O
consisting O
of O
Syk O
coupled O
to O
green O
fluorescent O
protein O
. O

As O
immunoglobulin O
transcription O
is O
mainly O
regulated O
by O
the O
B-cell O
transcription O
factors O
Oct2 O
and O
BOB.1/OBF.1 O
, O
we O
analyzed O
35 O
cases O
of O
LPHD O
, O
32 O
cases O
of O
cHD O
, O
and O
2 O
Hodgkin B
disease I
cell I
lines I
for O
the O
expression O
of O
these O
transcription O
factors O
and O
also O
in O
parallel O
for O
immunoglobulin O
expression O
. O

We O
investigated O
the O
expression O
of O
active O
NF-kappa O
B O
p65 O
( O
Rel O
A O
) O
in O
cases O
of O
mycosis O
fungoides O
( O
MF O
) O
and O
the O
effect O
of O
chemical O
inhibitors O
of O
NF-kappa O
B O
on O
apoptosis O
in O
cutaneous B
T I
cell I
lymphoma I
( I
CTCL I
) I
cell I
lines I
. O

Apoptosis O
after O
treatment O
with O
the O
NF-kappa O
B O
inhibitors O
gliotoxin O
, O
MG132 O
, O
BAY O
11-7082 O
, O
and O
BAY O
11-7085 O
was O
quantitatively O
measured O
in O
the O
CTCL B
cell I
lines I
HuT-78 I
and I
HH I
by O
propidium O
iodide O
( O
PI O
) O
/cell O
cycle O
analysis O
for O
detection O
of O
a O
hypodiploid O
( O
sub-G O
( O
0 O
) O
) O
population O
and O
by O
determination O
of O
increased O
Annexin O
V/7-amino-actinomycin O
D O
( O
7-AAD O
) O
expression O
. O

Nuclear O
expression O
of O
p65 O
( O
Rel O
A O
) O
before O
and O
after O
treatment O
with O
the O
various O
inhibitory O
compounds O
was O
measured O
by O
immunofluorescence O
staining O
in O
each O
CTCL B
cell I
line I
. O

Compared O
with O
untreated O
control O
cells O
, O
a O
marked O
increase O
in O
apoptosis O
, O
a O
significant O
decrease O
in O
NF-kappa O
B O
DNA-binding O
activity O
, O
and O
a O
marked O
decrease O
in O
nuclear O
p65 O
( O
Rel O
A O
) O
expression O
were O
seen O
in O
cells O
from O
both O
CTCL B
cell I
lines I
after O
chemical O
NF-kappa O
B O
inhibition O
. O

In O
CTCL B
cell I
lines I
, O
the O
significant O
decrease O
in O
nuclear O
NF-kappa O
B O
expression O
and O
the O
marked O
increase O
in O
spontaneous O
apoptosis O
caused O
by O
chemical O
NF-kappa O
B O
inhibition O
suggest O
a O
critical O
role O
for O
NF-kappa O
B O
in O
the O
pathogenesis O
and O
tumor O
cell O
maintenance O
of O
CTCLs O
. O

Transient O
transfection O
studies O
showed O
that O
Tax O
activated O
the O
expression O
of O
a O
luciferase O
gene O
regulated O
by O
two O
copies O
of O
an O
AP-1 O
site O
in O
the O
human B
Jurkat I
T-cell I
line I
. O

In O
addition O
, O
Tax703 O
and O
Tax O
, O
but O
not O
TaxM22 O
, O
converted O
cell O
growth O
of O
a O
mouse B
T-cell I
line I
from O
being O
interleukin O
( O
IL O
) O
-2-dependent O
to O
being O
IL-2-independent O
. O

Unlike O
the O
wild-type O
Tax O
, O
Tax703 O
and O
TaxM22 O
only O
weakly O
activated O
the O
AP-1 O
site O
in O
the O
T-cell B
line I
. O

Activation O
of O
transcription O
through O
the O
AP-1 O
site O
in O
Jurkat B
cells I
by O
JunD O
and/or O
Fra-2 O
was O
weak O
. O

These O
designer O
`` O
HIV-rtTA O
'' O
viruses O
replicate O
in O
a O
strictly O
dox-dependent O
manner O
both O
in O
a O
T-cell B
line I
and O
in O
primary O
blood O
cells O
, O
and O
the O
rate O
of O
replication O
can O
be O
fine-tuned O
by O
simple O
variation O
of O
the O
dox O
concentration O
. O

Synovial O
fluid O
induced O
nuclear O
factor-kappaB O
DNA O
binding O
in O
a O
monocytic B
cell I
line I
. O

OBJECTIVE O
: O
To O
determine O
the O
effects O
of O
synovial O
fluids O
( O
SF O
) O
on O
DNA O
binding O
activity O
of O
transcription O
factor O
nuclear O
factor-kappaB O
( O
NF-kappaB O
) O
in O
the O
Mono B
Mac I
6 I
monocytic/macrophage I
cell I
line I
as O
a O
model O
for O
the O
interaction O
between O
SF O
and O
synovial O
tissue O
macrophages O
in O
arthritis O
. O

METHODS O
: O
Mono B
Mac I
6 I
cells I
were O
incubated O
with O
SF O
from O
the O
knee O
joints O
of O
human O
subjects O
with O
rheumatoid O
arthritis O
( O
RA O
) O
, O
undifferentiated O
seronegative O
oligoarthritis O
, O
and O
osteoarthritis O
( O
OA O
) O
. O

Nuclear O
extracts O
prepared O
from O
the O
Mono B
Mac I
6 I
cells I
and O
RA O
synovial O
tissue O
were O
analyzed O
by O
electrophoretic O
mobility O
shift O
analysis O
( O
EMSA O
) O
for O
NF-kappaB O
DNA O
binding O
proteins O
. O

RESULTS O
: O
Induction O
of O
NF-kappaB O
DNA O
binding O
by O
the O
p65 O
( O
RelA O
) O
/p50 O
heterodimer O
was O
observed O
in O
response O
to O
incubation O
of O
Mono B
Mac I
6 I
cells I
with O
SF O
( O
20 O
% O
in O
culture O
medium O
) O
from O
5 O
of O
8 O
subjects O
with O
RA O
, O
4 O
of O
5 O
with O
OA O
, O
and O
none O
of O
3 O
with O
undifferentiated O
seronegative O
oligoarthritis O
. O

Unexpectedly O
, O
a O
slowly O
migrating O
SF O
inducible O
NF-kappaB O
-binding O
complex O
was O
observed O
in O
EMSA O
of O
Mono B
Mac I
6 I
cells I
after O
incubation O
with O
SF O
from O
5 O
of O
8 O
RA O
and O
2 O
of O
5 O
OA O
subjects O
. O

We O
demonstrated O
that O
expression O
of O
dnEts O
markedly O
suppressed O
HIV-1 O
infection O
of O
a O
T B
cell I
line I
. O

We O
have O
designed O
a O
Nef O
protein O
that O
is O
readily O
expressed O
in O
T-cell B
lines I
and O
whose O
function O
is O
inducibly O
activated O
. O

Using O
this O
inducible O
Nef O
, O
we O
also O
compared O
the O
specific O
requirements O
for O
CD4 O
and O
HLA-A2 O
downmodulation O
in O
a O
SupT1 B
T-cell I
line I
. O

Confocal O
microscopy O
further O
demonstrated O
that O
exogenously O
expressed O
PKCtheta O
and O
IKKss O
colocalize O
in O
the O
membrane O
of O
CD3/CD28-costimulated B
Jurkat I
T I
cells I
. O

Constitutively O
active O
but O
not O
kinase-inactive O
PKCtheta O
activated O
IKKbeta O
in O
Jurkat B
T I
cells I
. O

SKAT-2 O
is O
tissue O
restricted O
in O
expression O
at O
the O
RNA O
level O
, O
detectable O
only O
in O
brain O
and O
at O
low O
levels O
in O
kidney O
and O
spleen O
and O
few O
hematopoietic B
cell I
lines I
. O

In O
transient O
transfection O
experiments O
in O
phorbol O
12-myristate O
13-acetate/ionomycin-stimulated O
EL4 B
cells I
, O
SKAT-2 O
was O
found O
to O
up-regulate O
the O
activity O
of O
the O
IL-4 O
but O
not O
the O
IL-5 O
promoter O
, O
contrasting O
with O
the O
ability O
of O
GATA-3 O
to O
activate O
both O
promoters O
. O

This O
result O
was O
confirmed O
using O
clones O
of O
EL4 B
cells I
stably O
expressing O
an O
inducible O
form O
of O
SKAT-2 O
, O
thus O
SKAT-2 O
is O
a O
novel O
Th2-specific O
gene O
that O
may O
play O
a O
role O
in O
selective O
regulation O
of O
cytokine O
genes O
in O
T O
cells O
. O

In O
the O
five-protein O
system O
, O
Hip O
prevents O
inhibition O
of O
assembly O
by O
the O
hsp70 O
co-chaperone O
BAG-1 O
, O
and O
cotransfection O
of O
Hip O
with O
BAG-1 O
opposes O
BAG-1 O
reduction O
of O
steroid O
binding O
activity O
in O
COS B
cells I
. O

A O
transient O
transfection O
study O
showed O
that O
Tax O
can O
activate O
transcription O
through O
the O
AP-1-binding O
site O
in O
a O
human B
T I
cell I
line I
, O
whereas O
any O
combination O
of O
AP-1 O
proteins O
did O
so O
much O
less O
than O
Tax O
, O
indicating O
that O
the O
activation O
of O
the O
AP-1 O
site O
by O
Tax O
may O
require O
a O
mechanism O
other O
than O
the O
induction O
of O
AP-1 O
mRNA O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
effect O
of O
PCBs O
on O
immune O
system O
by O
assessing O
apoptotic O
cell O
death O
in O
human B
monocytic I
U937 I
cells I
. O

In O
contrast O
, O
3 O
, O
3 O
' O
, O
4 O
, O
4 O
' O
, O
5-PeCB O
, O
a O
congener O
of O
coplanar O
structure O
, O
as O
well O
as O
2 O
, O
3 O
, O
7 O
, O
8-TCDD O
did O
not O
induce O
apoptosis O
in O
these O
human O
monocytic O
cells O
, O
although O
they O
potently O
induced O
CYP O
1A1 O
in O
human B
hepatoma I
Hep I
G2 I
cells I
. O

The O
cytokine-dependent B
murine I
myeloid I
FDC-P1 I
and O
human B
erythroleukemic I
TF-1 I
cell I
lines I
were O
transformed O
to O
grow O
in O
response O
to O
deregulated O
Raf O
expression O
in O
the O
absence O
of O
exogenous O
cytokines O
. O

Continuous O
deltaRaf O
expression O
prevented O
apoptosis O
in O
the O
absence O
of O
exogenous O
cytokines O
and O
altered O
the O
morphology O
of O
the O
FD/deltaRaf O
: O
ER O
cells O
as O
they O
grew O
in O
large O
aggregated O
masses O
( O
> O
100 O
cells O
) O
whereas O
the O
parental B
cytokine-dependent I
FDC-P1 I
cells I
grew O
in O
smaller O
grape-like O
clusters O
( O
< O
10 O
cells O
) O
. O

FD/deltaRaf-1 B
: I
ER I
cells I
growing O
in O
response O
to O
Raf O
activation O
displayed O
decreased O
levels O
of O
the O
Mac-2 O
and O
Mac-3 O
molecules O
on O
their O
cell O
surface O
. O

Expression O
of O
activated O
Raf O
oncoproteins O
also O
abrogated O
cytokine O
dependency O
and O
prevented O
apoptosis O
of O
TF-1 B
cells I
. O

These O
Raf-responsive B
cell I
lines I
will O
be O
useful O
in O
elucidating O
the O
roles O
of O
the O
MAP O
kinase O
cascade O
on O
hematopoietic O
cell O
differentiation O
and O
malignant O
transformation O

In O
this O
study O
, O
we O
constructed O
wild O
and O
mutated O
types O
of O
human O
IL-13R O
alpha O
1 O
, O
and O
analyzed O
IL-4 O
and O
IL-13 O
signals O
using O
an O
IL-13R O
alpha O
1 O
-transfected O
human B
B I
cell I
line I
. O

Janus O
tyrosine O
kinase O
( O
Jak O
) O
3 O
and O
transcription O
factors O
Stat5a O
and O
Stat5b O
are O
essential O
for O
the O
proliferation O
of O
normal O
T O
cells O
and O
are O
constitutively O
hyperactivated O
in O
both O
HTLV-1-transformed B
human I
T I
cell I
lines I
and O
lymphocytes O
isolated O
from O
HTLV-1-infected O
patients O
; O
therefore O
, O
a O
critical O
role O
for O
the O
Jak3-Stat5 O
pathway O
in O
the O
progression O
of O
this O
disease O
has O
been O
postulated O
. O

We O
recently O
reported O
that O
tyrphostin O
AG-490 O
selectively O
blocked O
IL-2 O
activation O
of O
Jak3/Stat5 O
and O
growth O
of O
murine B
T I
cell I
lines I
. O

Here O
we O
demonstrate O
that O
disruption O
of O
Jak3/Stat5a/b O
signaling O
with O
AG-490 O
( O
50 O
& O
mgr O
; O
M O
) O
blocked O
the O
proliferation O
of O
primary O
human O
T O
lymphocytes O
, O
but O
paradoxically O
failed O
to O
inhibit O
the O
proliferation O
of O
HTLV-1-transformed B
human I
T I
cell I
lines I
, O
HuT-102 B
and O
MT-2 B
. O

In O
the O
present O
study O
, O
we O
have O
demonstrated O
that O
, O
unlike O
resting O
cells O
, O
activation O
of O
cycling O
human O
mature O
PBT O
lymphocytes O
, O
and O
T B
lymphocyte I
leukemia I
cell I
lines I
is O
accompanied O
by O
the O
accumulation O
of O
RXRalpha O
mRNA O
and O
protein O
. O

Transfection O
analysis O
in O
Jurkat B
cells I
, O
using O
RXRE-dependent O
reporter O
assays O
, O
showed O
that O
RXRalpha O
accumulated O
during O
T O
cell O
activation O
was O
transcriptionally O
inactive O
. O

For O
functional O
characterization O
of O
both O
promoters O
, O
plasmids O
in O
which O
reporter O
genes O
were O
placed O
under O
the O
control O
of O
a O
series O
of O
truncated O
or O
mutated O
promoter O
fragments O
were O
transfected O
to O
human B
hematopoietic I
cell I
lines I
. O

Although O
both O
isomers O
were O
expressed O
in O
human B
erythroid-megakaryocytic I
cell I
lines I
, O
megakaryocytic O
maturation O
with O
loss O
of O
erythroid O
phenotype O
induced O
by O
phorbol O
12-myristate O
13-acetate O
( O
PMA O
) O
resulted O
in O
exclusive O
downregulation O
of O
fNF-E2 O
, O
suggesting O
that O
fNF-E2 O
promoter O
is O
more O
erythroid O
specific O
. O

MATERIALS O
AND O
METHODS O
: O
We O
screened O
a O
panel O
of O
acute B
myeloid I
leukemia-derived I
cell I
lines I
for O
TNF- O
alpha O
-responsiveness O
. O

In O
two O
lines O
( O
OCI-AML-1 B
, O
OCI-AML-11 B
) O
, O
TNF- O
alpha O
acted O
as O
an O
apoptotic O
agent O
; O
in O
others O
( O
HU-3 B
, O
M-07e B
, O
TF-1 B
) O
, O
it O
had O
the O
opposite O
effect O
, O
preventing O
apoptosis O
and O
inducing O
proliferation O
. O

Supporting O
this O
notion O
, O
TNF-alpha O
-induced O
upregulation O
of O
GM-CSF O
mRNA O
levels O
and O
protein O
secretion O
in O
the O
TNF-alpha O
-proliferative O
, O
but O
not O
in O
the O
TNF-alpha-apoptotic B
cell I
lines I
. O

We O
show O
for O
the O
first O
time O
that O
TNF-alpha-treated B
cell I
lines I
producing O
no O
or O
only O
minimal O
amounts O
of O
GM-CSF O
demonstrate O
an O
apoptotic O
phenotype O
, O
while O
cell O
lines O
with O
high O
GM-CSF O
expression O
rates O
can O
escape O
from O
growth O
arrest O
or O
even O
apoptosis O
. O

The O
binding O
affinities O
of O
the O
different O
T B
cell I
preparations I
for O
dexamethasone O
were O
similar O
. O

A O
number O
of O
leukemia B
cell I
lines I
in O
continuous O
culture O
were O
also O
subjected O
to O
the O
GR O
assay O
, O
and O
the O
results O
were O
correlated O
with O
the O
sensitivity O
of O
these O
cell B
lines I
to O
glucocorticoid O
steroids O
in O
vitro O
. O

GR O
was O
identified O
in O
all O
the O
12 O
malignant B
continuous I
white I
cell I
lines I
studied O
. O

Distribution O
of O
the O
surface O
markers O
in O
the O
leukemic B
cell I
lines I
did O
not O
relate O
to O
the O
GR O
concentration O
. O

In O
this O
paper O
, O
TNF-alpha O
mRNA O
is O
shown O
to O
be O
highly O
induced O
in O
a O
murine B
T I
cell I
clone I
by O
stimulation O
with O
T O
cell O
receptor O
( O
TCR O
) O
ligands O
or O
by O
calcium O
ionophores O
alone O
. O

Differences O
in O
expression O
of O
transcription O
factor O
AP-1 O
in O
human B
promyelocytic I
HL-60 I
cells I
during O
differentiation O
towards O
macrophages O
versus O
granulocytes O
. O

Commitment O
of O
HL-60 B
cells I
to O
macrophage O
or O
granulocytic O
differentiation O
was O
achieved O
by O
incubation O
with O
4 O
beta-phorbol O
12-myristate O
13-acetate O
( O
PMA O
) O
for O
30-60 O
min O
or O
with O
dimethyl O
sulphoxide O
( O
DMSO O
) O
for O
24 O
h O
respectively O
. O

When O
HL-60 B
cells I
were O
treated O
with O
sodium O
butyrate O
, O
which O
induced O
monocytic O
differentiation O
, O
a O
remarkable O
increase O
in O
AP-1 O
binding O
activity O
was O
detected O
. O

Treatment O
of O
HL-60 B
cells I
with O
1 O
alpha O
, O
25-dihydroxyvitamin O
D3 O
, O
another O
monocytic O
differentiation O
agent O
, O
induced O
a O
weak O
, O
but O
appreciable O
, O
increase O
in O
AP-1 O
activity O
. O

Furthermore O
, O
addition O
of O
sodium O
butyrate O
or O
1 O
alpha O
, O
25-dihydroxyvitamin O
D3 O
to O
HL-60 B
cells I
induced O
the O
expression O
of O
c-fos O
, O
c-jun O
, O
jun O
B O
and O
jun O
D O
proto-oncogenes O
. O

In O
contrast O
, O
when O
HL-60 B
cells I
were O
treated O
with O
retinoic O
acid O
, O
a O
granulocytic O
differentiation O
inducer O
, O
no O
enhanced O
AP-1 O
binding O
activity O
was O
observed O
, O
and O
only O
a O
weak O
increase O
in O
jun O
D O
mRNA O
level O
was O
detected O
. O

These O
data O
indicate O
that O
formation O
of O
AP-1 O
is O
not O
required O
for O
the O
induction O
of O
HL-60 B
differentiation O
towards O
granulocytes O
, O
whereas O
induction O
of O
monocytic O
differentiation O
is O
correlated O
with O
an O
increase O
in O
AP-1 O
activity O
. O

The O
differential O
expression O
of O
AP-1 O
activity O
may O
be O
critical O
in O
the O
differentiation O
of O
HL-60 B
cells I
towards O
monocytic O
or O
granulocytic O
lineages O

'Activation-labile O
' O
glucocorticoid-receptor O
complexes O
of O
a O
steroid-resistant O
variant O
of O
CEM-C7 B
human I
lymphoid I
cells I
. O

We O
report O
here O
that O
DEAE-cellulose O
chromatography O
of O
steroid-receptor O
complexes O
from O
CEM-C7 B
, O
a O
cloned B
human I
leukaemic I
T-cell I
line I
sensitive O
to O
the O
cytolytic O
action O
of O
glucocorticoids O
, O
and O
its O
steroid-resistant B
subclone I
4R4 I
demonstrated O
that O
steroid O
receptors O
of O
clone B
4R4 I
can O
not O
form O
stable O
activated O
complexes O
. O

This O
defines O
a O
new O
defect O
in O
receptor O
action O
, O
activation O
lability O
( O
r+act1 O
) O
, O
which O
is O
unlike O
either O
the O
r- B
, I
r+nt- I
, I
or I
r+nti I
phenotypes I
previously O
described O
for O
mouse B
lymphoid I
variants I
. O

We O
have O
previously O
shown O
that O
a O
fragment O
containing O
bp O
-95 O
to O
+27 O
of O
the O
mouse O
GM-CSF O
promoter O
can O
confer O
inducibility O
to O
reporter O
genes O
in O
the O
human B
Jurkat I
T-cell I
line I
. O

DNaseI O
footprint O
and O
electrophoretic O
mobility O
shift O
assay O
analyses O
performed O
with O
MLA-144 B
T I
cell I
nuclear O
extracts O
demonstrated O
that O
this O
49-bp O
region O
contains O
a O
nuclear O
protein O
binding O
region O
that O
includes O
consensus O
AP-1 O
and O
Elf-1 O
binding O
sites O
. O

In O
vitro-transcribed O
and O
-translated O
Elf-1 O
protein O
bound O
specifically O
to O
the O
Elf-1 O
site O
, O
and O
Elf-1 O
antisera O
competed O
and O
super O
shifted O
nuclear O
protein O
complexes O
present O
in O
MLA-144 B
nuclear O
extracts O
. O

Transient O
transfection O
studies O
in O
MLA-144 B
T I
cells I
revealed O
that O
constructs O
containing O
mutations O
in O
the O
AP-1 O
site O
almost O
completely O
abolished O
CAT O
activity O
while O
mutation O
of O
the O
Elf-1 O
site O
or O
the O
NF-IL-3 O
site O
, O
a O
previously O
described O
nuclear O
protein O
binding O
site O
( O
bp. O
-155 O
to O
-148 O
) O
in O
the O
IL-3 O
promoter O
, O
reduced O
CAT O
activity O
to O
< O
25 O
% O
of O
the O
activity O
given O
by O
wild-type O
constructs O
. O

Glucocorticoid O
receptor O
activation O
and O
inactivation O
in O
c O
ultured B
human I
lymphocytes I
. O

Although O
glucocorticoids O
are O
not O
cytolytic O
for O
and O
do O
not O
inhibit O
the O
growth O
of O
the O
IM-9 B
line I
of O
cultured B
human I
lymphoblasts I
, O
these O
cells O
have O
a O
high O
steroid-binding O
capacity O
. O

The O
inactivation O
of O
glucocorticoid O
receptors O
that O
occurs O
when O
cytosol O
from O
normal O
IM-9 B
cells I
is O
incubated O
at O
25 O
degrees O
C O
is O
inhibited O
by O
molybdate O
, O
vanadate O
, O
fluoride O
, O
ATP O
, O
and O
several O
other O
nucleotides O
. O

To O
study O
variations O
in O
glucocorticoid O
receptor O
levels O
during O
the O
cell O
cycle O
, O
we O
have O
separated O
mitogen-stimulated B
human I
peripheral I
lymphocytes I
and O
rat O
lymph O
node O
cells O
by O
unit O
gravity O
sedimentation O
and O
measured O
glucocorticoid O
binding O
in O
the O
resultant O
fractions O
. O

A O
2- O
to O
3-fold O
increase O
in O
glucocorticoid O
receptor O
sites O
per O
cell O
, O
for O
cells O
in O
the O
S O
and O
post-S O
phase O
over O
those O
in O
G0 O
and O
G1 O
, O
was O
observed O
with O
both O
nonstimulated O
rat O
lymph O
node O
cell O
suspensions O
and O
concanavalin B
A-stimulated I
human I
peripheral I
lymphocytes I
. O

We O
have O
used O
the O
leukocyte O
migration O
inhibition O
( O
LMI O
) O
response O
to O
assay O
the O
response O
to O
several O
potential O
breast O
cancer-related O
antigens O
, O
including O
MuMTV O
, O
MPMV O
, O
and O
a O
breast B
cancer I
cultured I
cell I
line I
, O
MCF-7 B
, O
in O
96 O
breast O
cancer O
patients O
, O
in O
32 O
women O
with O
benign O
breast O
disease O
, O
and O
in O
67 O
normal O
women O
. O

Nuclear O
extracts O
from O
unstimulated B
cells I
of O
the O
human B
monocytic I
cell I
line I
, O
Mono B
Mac I
6 I
, O
contain O
one O
specific O
binding O
protein O
( O
complex O
II O
) O
, O
consistent O
with O
a O
constitutive O
p50 O
homodimer O
. O

Stimulation O
of O
Mono B
Mac I
6 I
cells I
with O
LPS O
will O
increase O
complex O
II O
and O
will O
strongly O
induce O
a O
second O
specific O
complex O
( O
complex O
I O
) O
, O
which O
represents O
the O
p50/65 O
heterodimer O
. O

In O
T O
lymphocytes O
, O
triggering O
of O
the O
T O
cell O
receptor O
( O
TCR O
) O
induces O
several O
signaling O
cascades O
which O
ultimately O
synergize O
to O
induce O
the O
activity O
of O
the O
nuclear O
factor O
of O
activated O
T O
cells O
( O
NFAT B
) O
, O
a O
DNA O
binding O
complex O
critical O
to O
the O
inducibility O
and O
T O
cell O
specificity O
of O
the O
T O
cell O
growth O
factor O
interleukin O
2 O
. O

Calcium O
signals O
are O
important O
for O
NFAT B
induction O
, O
and O
recent O
studies O
have O
identified O
calcineurin O
, O
a O
calcium-calmodulin O
dependent O
serine-threonine O
phosphatase O
, O
as O
a O
prominent O
component O
of O
the O
calcium O
signaling O
pathway O
in O
T O
cells O
. O

We O
then O
examined O
the O
ability O
of O
the O
affinity O
gel O
to O
recognize O
cytosolic O
[ O
3H O
] O
triamcinolone O
acetonide-receptor O
complexes O
from O
the O
corticoid-sensitive B
( I
CS I
) I
and I
-resistant I
strains I
of I
mouse I
lymphoma I
P1798 I
, O
from O
CS O
lymphocytes O
of O
patients O
with O
chronic O
lymphatic O
leukemia O
, O
and O
from O
a O
CS B
clone I
of O
human O
leukemic O
lymphoblasts O
in O
tissue O
culture O
( O
CH6 B
) O
. O

Whereas O
the O
immunoaffinity O
column O
retained O
70 O
to O
84 O
% O
of O
the O
58- O
to O
62-A O
( O
Stokes O
radius O
) O
[ O
3H O
] O
triamcinolone O
acetonide-receptor O
complexes O
characteristic O
of O
the O
CS B
mouse I
and I
human I
lymphocytes I
, O
it O
failed O
to O
recognize O
the O
27- O
to O
28-A O
( O
Stokes O
radius O
) O
glucocorticoid O
receptor O
present O
in O
corticoid-resistant O
mouse B
lymphoma I
P1798 I
cells I
. O

Increased O
glucocorticoid O
receptor O
levels O
in O
antigen-stimulated B
lymphocytes I
. O

PC-PLC-activated O
hydrolysis O
of O
PC O
was O
found O
to O
induce O
bona O
fide O
p50/p65 O
NF-kappa O
B O
binding O
activity O
in O
three O
different O
cell B
lines I
of O
human O
or O
murine O
origin O
. O

No O
significant O
changes O
in O
the O
turnover O
of O
other O
cellular O
phospholipids O
were O
detected O
in O
PC-PLC-treated B
cells I
. O

In O
human B
monocytic I
and I
lymphoblastoid I
T-cell I
lines I
, O
induction O
of O
NF-kappa O
B O
by O
PC-PLC O
resulted O
in O
clear O
induction O
of O
luciferase O
expression O
vectors O
placed O
under O
the O
control O
of O
synthetic O
kappa O
B O
enhancers O
or O
wild O
type O
, O
but O
not O
kappa O
B-mutated O
, O
HIV O
long O
terminal O
repeat O
constructs O
. O

Human O
peripheral O
blood O
T O
cells O
, O
stimulated O
with O
PMA O
for O
48 O
h O
( O
PMA B
blasts I
) O
, O
were O
incubated O
with O
IL-2 O
in O
the O
presence O
of O
incremental O
dosages O
of O
dexamethasone O
( O
Dex O
; O
10 O
( O
-5 O
) O
-10 O
( O
-9 O
) O
M O
) O
. O

Dex O
inhibited O
the O
IL-2-dependent O
proliferation O
of O
PMA B
blasts I
in O
a O
dose-dependent O
fashion O
( O
IC50 O
, O
5 O
x O
10 O
( O
-8 O
) O
M O
) O
. O

IL-2-dependent O
IL-2R O
alpha O
expression O
in O
PMA B
blasts I
and O
NF-kB O
induction O
in O
resting O
human O
T O
cells O
were O
also O
inhibited O
by O
Dex O
. O

These O
results O
demonstrate O
that O
glucocorticoids O
inhibit O
preactivated B
T I
cells I
by O
down-regulating O
signal O
transduction O
through O
IL-2R O
. O

The O
relationship O
between O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV-1 O
) O
infection O
and O
the O
induction O
of O
NF-kappa O
B O
binding O
activity O
was O
examined O
in O
a O
myeloid B
cell I
model I
of O
HIV-1 O
infection O
derived O
from O
the O
PLB-985 B
cell I
line I
. O

Chronic O
infection O
of O
PLB-985 B
cells I
led O
to O
increased O
monocyte-specific O
surface O
marker O
expression O
, O
increased O
c-fms O
gene O
transcription O
, O
and O
morphological O
alterations O
consistent O
with O
differentiation O
along O
the O
monocytic O
pathway O
. O

PLB-IIIB B
cells I
displayed O
a O
constitutive O
NF-kappa O
B-like O
binding O
activity O
that O
was O
distinct O
from O
that O
induced O
by O
tumor O
necrosis O
factor O
alpha O
or O
phorbol O
12-myristate O
13-acetate O
treatment O
of O
the O
parental B
PLB-985 I
cell I
line I
. O

Transient O
cotransfection O
experiments O
demonstrated O
that O
RelA O
and O
NFKB1 O
expression O
maximally O
stimulated O
HIV-1 O
LTR- O
and O
NF-kappa O
B-dependent O
reporter O
genes O
; O
differences O
in O
NF-kappa O
B-like O
binding O
activity O
were O
also O
reflected O
in O
higher O
constitutive O
levels O
of O
NF-kappa O
B-regulated O
gene O
expression O
in O
HIV-1-infected B
myeloid I
cells I
. O

Presence O
of O
estrogen-binding O
sites O
on O
macrophage-like O
synoviocytes O
and O
CD8+ B
, I
CD29+ I
, I
CD45RO+ I
T I
lymphocytes I
in O
normal O
and O
rheumatoid O
synovium O
. O

Double O
immunostaining O
with O
the O
anti-ER O
MAb O
and O
with O
specific O
MAb O
to O
detect O
different O
macrophage O
antigens O
( O
Ber-MAC3 O
, O
MAC387 O
, O
CD68 O
) O
and O
CD8+ B
T I
cell I
subsets I
( O
CD29+ B
, O
CD45RO+ B
and O
CD29- B
, O
CD45RO- B
) O
was O
performed O
. O

Immunostaining O
showed O
the O
estrogen O
receptor-positive O
cells O
to O
be O
the O
macrophage-like O
synoviocytes O
and O
the O
CD8+ B
, O
CD29+ B
T I
cells I
both O
in O
RA O
and O
in O
control O
synovial O
tissues O
. O

It O
is O
conceivable O
that O
the O
immunomodulatory O
activity O
exerted O
by O
estrogens O
is O
at O
least O
partly O
mediated O
through O
their O
interaction O
with O
EBS O
that O
are O
present O
on O
macrophage-like O
synoviocytes O
, O
functioning O
as O
antigen-processing O
and O
antigen-presenting O
cells O
, O
and O
on O
antigen-experienced B
( I
memory I
) I
CD8+ I
T I
lymphocytes I
( O
CD29+ B
, O
CD45RO+ B

